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A series of symmetrically bis-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl
moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on
docking studies and utilizing for the ﬁrst time an extra hydrophobic binding cleft of AT1 receptor. The
synthesized analogs were evaluated for their in vitro antagonistic activities (pA2 values) and binding af-
ﬁnities (elogIC50 values) to the Angiotensin II AT1 receptor. Among them, the potassium (elogIC50¼ 9.04)
and the sodium (elogIC50 ¼ 8.54) salts of 4-butyl-N,N0-bis{[20-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}
imidazolium bromide (12a and 12b, respectively) as well as its free acid 11 (elogIC50 ¼ 9.46) and the 4-
butyl-2-hydroxymethyl-N,N0-bis{[20-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (14)
(elogIC50¼8.37, pA2¼8.58) showedhighbinding afﬁnity to theAT1 receptor andhigh antagonistic activity
(potency). The potencywas similar or even superior to that of Losartan (elogIC50¼ 8.25, pA2¼ 8.25). On the
contrary, 2-butyl-N,N0-bis{[20-[2H-tetrazol-5-yl)]biphenyl-4-yl]methyl}imidazolium bromide (27)
(elogIC50 ¼ 5.77) and 2-butyl-4-chloro-5-hydroxymethyl-N,N0-bis{[20-[2H-tetrazol-5-yl)]biphenyl-4-yl]
methyl}imidazolium bromide (30) (elogIC50¼ 6.38) displayed very lowbinding afﬁnity indicating that the
orientation of the n-butyl group is of primary importance. Docking studies of the representative highly
active 12b clearly showed that this molecule has an extra hydrophobic binding feature compared to pro-
totype drug Losartan and it ﬁts to the extra hydrophobic cavity. These results may contribute to the dis-
covery and development of a new class of biologically active molecules through bis-alkylation of the
imidazole ring by a convenient and cost effective synthetic strategy.
 2013 Elsevier Masson SAS. All rights reserved., University of Patras, 26500 Patras, Greece. Tel.: þ30 6944514458.
Agelis), imats@upatras.gr (J. Matsoukas).
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G. Agelis et al. / European Journal of Medicinal Chemistry 62 (2013) 352e370 3531. Introduction such as the biphenylmethyl group at the 1-position [12], a linear
alkyl group at the 2-position [13,14] and an acidic group, like tet-The RenineAngiotensin System (RAS) plays a key role in regu-
lating cardiovascular homeostasis and electrolyte/ﬂuid balance in
normotensive and hypertensive subjects. In the RAS the biological
actions of Angiotensin II (ANGII), such as vasoconstriction, release
of aldosterone, stimulation of sympathetic transmission and cel-
lular growth are mediated by the Angiotensin type 1 (AT1) re-
ceptor. Consequently, the RAS has been the prime target for the
therapy of cardiovascular diseases and non-peptide AT1 receptor
antagonists have been developed to speciﬁcally block it [1,2]. In
speciﬁc, the DuPont group pursued a study in this ﬁeld and
developed Losartan, the ﬁrst orally effective non-peptide antago-
nist, which is in vivo metabolized to the more potent EXP 3174 [3]
(Fig. 1). Since then, numerous new antagonists have been reported
by various research groups with nine of them in the clinic i.e.
Candesartan [4], Valsartan [5], Irbesartan [6], Telmisartan [7],
Olmesartan [8] which have been established as strong AT1 Re-
ceptor Blockers (ARBs). On 25 February 2011, the U.S. Food and
Drug Administration (FDA) approved Azilsartan medoxomil [9,10]
which is a newer-generation ARB, for the treatment of high
blood pressure in adults. Despite the plethora of treatment options
for the management of hypertension, 56% of patients do not have
their blood pressure under adequate control [11] suggesting the
need for the development of improved ARBs.
Themajority of selective ARBs have resulted from the strategy of
modifying or replacing several pharmacophore groups of Losartan.
Structure Activity Relationship (SAR) studies of Losartan and other
imidazole blockers have been reported. Lipophilic substituents,Fig. 1. Selected bis-alkylated butylimidazole synthesized analogs, Losartan, EXrazole, CO2H, or NHSO2CF3 on the biphenylmethyl group [4,7,15],
are required for antagonistic activity. Furthermore, the DuPont
group recommended a lipophilic and electron-withdrawing group,
such as iodine or CF3, as a substituent at the 4-position and a small-
sized group at the 5-position, such as CH2OH, CH2OMe, or CO2H,
which is capable of forming a hydrogen bond [8,9].
We recently described a series of N-substituted 5-butylimidazole
analogs as potent ARBs via efﬁcient synthetic routes, allowing the
facile introduction of substituents on the imidazole ring [16e19].
Based on these ﬁndings, we rationally designed a new class of N,N0-
symmetrically bis-substituted butylimidazole analogs as potent
ARBs that occupy an extra hydrophobic binding cleft (Fig.1). Thus, in
the present work, a series of new compounds has been synthesized
bearing (i) an imidazole ring; (ii) the biphenylmethyl moiety
at theN-1 andN-3of theheterocyclic ring; (iii) anacidic functionality
such as a tetrazole group or its bioisostere carboxy group ortho
substituted at the biphenylmethyl group, and (iv) the n-butyl chain
substituted on the heterocyclic ring at the C-2 or C-5 for efﬁcient
binding to the receptor. Furthermore, the hydroxymethyl group was
introduced at the C-2 as well as a halogen atom at the C-4 of the
imidazole ring, since the chloro substituent in the DuPont series
interacts with a lipophilic pocket of the receptor [10].
These unusual analogs were in vitro evaluated by means of their
binding afﬁnities for the human AT1 receptor, as well as for their
ability to inhibit the contractility effect of ANGII in isolated rat
uterus, compared to Losartan. The SAR study was performed and
the results suggested that the position of the n-butyl group in thisP 3174 (in vivo active metabolite) and ARBs marketed for hypertension.
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with the AT1 receptor. Finally, structure elucidation and detailed
docking studies have been carried out for the one of the most
potent synthetic analog 12b.
2. Results and discussion
2.1. Chemistry
In the current study, we initially examined various synthetic
protocols for the syntheses of 4(5)- and 2-substituted imidazoles as
key precursors for the preparation of N,N0-bis-alkylated analogs as
potentARBs. InScheme1, the synthesesof4(5)- and2-butylimidazole
via a synthetic sequence involving different N-protected imidazole
groups are depicted. Imidazole (1) was readily transformed through
a four-step synthetic pathway into the corresponding 1-trityl-imi-
dazole-4-carboxaldehyde (2a) [20,21]. Wittig reaction [22] of the
carboxaldehyde 2a by treatment with NaH and the nonstabilized
n-propyl triphenylphosphonium bromide (CH3CH2CH2PPh3Br) in
THF at rt furnished exclusively the Z-3 isomer 3a in excellent yield
(81%). The Z-conﬁgurationwas conﬁrmed by 1H NMRwhich showed
the presenceof twovinylic protons at 6.25 and5.60ppmasdoublet of
triplets, respectively (J¼ 11.6Hz). The latterwas subjected to catalytic
hydrogenationunderH2atmosphere (3bar) in thepresenceof Pd/Cat
ambient temperature for 2 h to give 4a in 92% yield. Finally,
demaskingofNHby treatmentwith20%TFA inCH2Cl2 in thepresence
of Et3SiH as scavenger furnished the target 4(5)-butylimidazole (5a).
Two routes were investigated for the conversion of 1 into the
2-butylimidazole (5b). In the ﬁrst approach (Scheme 1, Method A),
the N-1 was protected with the (N-dimethylamino)methyl group
under Mannich reaction conditions [23] resulting in 2b. Then, the
latter compound underwent smooth lithiation, which occurred
regiospeciﬁcally at the 2-position of the imidazole ring, upon
treatmentwith 1.6M n-BuLi in the presence of 1,3-dimethyl-3,4,5,6-
tetrahydro-2(1H)-pyrimidinone (DMPU) in THF at 78 C, followed
by electrophilic quenching with n-BuI [23,24]. Subsequent facile
acidic hydrolysis of the protective group afforded the corresponding
2-butylimidazole (5b) in 85% yield. In the second approach (Scheme
1, Method B), carboxaldehyde 2c was prepared as described in the
published procedure [25] using the N,N-dimethylsulfamoyl group
(DMAS) as NH protective group for the lithiation/electrophilicScheme 1. Reagents and conditions: (a) CH3CH2CH2PPh3Br, NaH (powdered, 95%), THF, rt, 8 h
(1.6 M in hexanes), DMPU, n-BuI, then 2 M HCl; (e) CH3CH2CH2PPh3Br, NaH (powdered, 95quenching sequence. Wittig reaction of 2c by treatment with NaH
and CH3CH2CH2PPh3Br in the presence of t-amyl alcohol [26,27] in
THFat 0 C to rt proceeded smoothly leading to the anticipatedoleﬁn
3c as amixture of Z and E isomers in a ratio of ca. 3:1 (as indicated by
HPLC) which were isolated and identiﬁed by NMR in 62% and 24%
yield, respectively. Then, the isomers were subjected to catalytic
hydrogenation to afford the saturated 4c in excellent yield (90%).
Finally, hydrolysis of4c in reﬂuxing 1.5NHCl [28] afforded the target
compound 2-butylimidazole (5b). The two methods are quite sim-
ilar with respect to yields and ﬁnal products, however, the former
was proven to be more efﬁcient in terms of total steps.
In Scheme 2, the syntheses of N,N0-bis-alkylated butylimidazole
derivatives bearing the biphenylmethyl moiety ortho substituted
either with the tetrazole or its bioisostere carboxy group as well as
the hydroxymethyl group at the 2-position are depicted. The N,N0-
bis-alkylation was generally accomplished under basic conditions
[29] followed by the treatment of the resulting salt with the
appropriate alkylating agent in excess. 4(5)-Butylimidazole (5a)
was converted to the corresponding quaternary salts 7 and 8 under
the general heterogeneous phase alkylation protocol. In particular,
the latter compounds were obtained using excess of the biphe-
nylmethyl bromides 6a and 6b [19] (2.3 equiv.) in the presence of
K2CO3 in anhydrous DMF at ambient temperature for 8 h in 78e82%
yields. Then, hydroxymethylation was promptly carried out in
a sealed tube by treatment with diisopropylethylamine and 37%
formalin in DMF at 85 C for 1 h [17,19]. This reaction proceeded
quantitatively as indicated by HPLC and led rapidly and exclusively
to the desired hydroxymethylated products 9 and 10. The trityl and
t-Bu groups of 7, 9 and 8, 10, respectively, were promptly removed
upon addition of 20% triﬂuoroacetic acid (TFA) in CH2Cl2 in the
presence of Et3SiH as scavenger to obtain the ﬁnal compounds 11,
13, 14, 15 in 72e85% yields. Finally, conversion of 11 into the cor-
responding water soluble bis-potassium and sodium salts 12a and
12b was accomplished by treatment with KOH and NaOH, respec-
tively, in MeOHeH2O at rt for 5 h in 80e83% yields. The 1H NMR
spectrum of 12a showed two methylene signals of N-1 and N-3 at
5.33 and 5.32 ppm as singlet peaks, the H-5 of imidazole at
7.41 ppm and H-2 at 8.93 ppm also as singlet peaks. In addition, the
hydroxymethylated analog of 14 showed the absence of the proton
at C-2 and the appearance of a singlet peak at 4.92 ppm, corre-
sponding to the hydroxymethylene protons.; (b) H2 (3 bar), 10% Pd/C, MeOH, rt, 2 h; (c) 20% TFA in CH2Cl2, Et3SiH, rt, 1 h; (d) n-BuLi
%), t-amyl alcohol, THF, 0 C to rt, 10 h; (f) 1.5 N HCl, THF, reﬂux, 2 h.
Scheme 2. Reagents and conditions: (a) K2CO3, DMF rt, 8 h; (b) 37% formalin, diisopropylethylamine, DMF, 80 C, 1 h; (c) 30% TFA in CH2Cl2, Et3SiH, rt, 1 h; (d) KOH, MeOHeH2O, rt,
5 h for 12a, NaOH, MeOHeH2O, rt, 5 h for 12b.
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butylimidazole derivatives bearing the biphenylmethyl moiety ortho
substituted either with the tetrazole or its bioisostere carboxy group
as well as the hydroxymethyl group at the 2-position are depicted.
The N,N0-bis-alkylation was advantageously accomplished under
basic conditionsbysolideliquidphase transfer catalysis (PTC) [30,31].
4(5)-Butylimidazole (5a) was converted to the corresponding halo-
genated analogs16cee by treatmentwithNXS (X¼Cl, Br, I) inDMF in
71e73% yields. The 1H NMR spectra of 16cee showed the absence of
theH-4 signal of the imidazole ring at 6.74 ppm. Furthermore, the 13C
NMRspectra showedanupﬁeld trend inC-4 chemical shifts produced
by bromine and iodine atoms for 16d and 16e, at 114.53 and
81.92 ppm, respectively, while the C-4 in the chloro derivative 16c
appeared at 124.24 ppm. Alkylation of 16cee with the alkylating
agent 6a, in the presence of K2CO3 and catalytic amount 18-crown-6-
ether to assist by chelating potassium in anhydrous THF under reﬂux
for 12 h, furnished the 17cee in 52e57% yields. PTC was also suc-
cessfully adopted for the syntheses of 18cee by treatment with 6b in
the presence of ﬁne powdered KOH and catalytic amount of 18-
crown-6-ether in anhydrous Tol at 80 C for 12 h in 58e64% yields.
Acidolysisofprotectivegroups in17ceeand18ceewasaccomplished
in the same manner and afforded 19cee and 20cee, respectively, in
73e82% yields. On the other hand, hydroxymethylation of 17cee and
18cee by treatment with 37% formalin in the presence of diisopro-
pylethylamine in DMF at 80 C for 1 h afforded 21cee and 22cee in
70e78% yields. The latter were subjected to acid hydrolysis with TFA,
resulting in 23cee and 24cee in 75e81% yields.
Identical methodology was employed for the preparation of 2-
butylimidazole analogs 27 and 28 (Scheme 4) through a two-step
sequence. In particular, alkylation of 5b by treatment with the
alkylating agents 6a and 6b and subsequent acid hydrolysis affor-
ded the expected analogs 27 and 28.Finally, in Scheme 5, the syntheses of bis-alkylated analogs 30
and 31 with the implementation of a facile PTC alkylatione
deprotection reaction sequence in one-pot procedure are depic-
ted. Thus, alkylation under basic conditions of the commercially
available (2-n-butyl-4-chloro-1H-imidazole-4yl)methanol 29,
which is an important precursor for the preparation of Losartan,
followed by acid hydrolysis, afforded the corresponding analogs 30
and 32 in 77% and 74% yield over two steps, respectively.
2.2. Structure elucidation of analog 12b
The chemical structure of 12b (Fig. 2) has been elucidated using
a combination of 2D DQF-COSY and 2D ROESY experiments
(Table 1). The alkyl chain of the molecule was easily identiﬁed from
the 2D DQF-COSY experiment, the multiplicity and integration of
the peaks (Fig. 2). Due to the asymmetry of the molecule the aro-
matic biphenyl protons showed distinct resonances conﬁrmed by
the integration of the peaks (see the alkyl chain extended only to
one side of biphenyltetrazole moiety). The H10 and H100 protons
are magnetically un-equivalent and are depicted as separate single
peaks (Fig. 2). 2D DQF-COSY (Supporting information SF1) made
possible to assign all aromatic peaks in combinationwith 2D ROESY
experiment. H10 showed ROE with the single peak at 6.85 ppm,
which according to the integration corresponds to the resonance of
four protons. These were assigned as the H12, H13, H15, H16 pro-
tons of the aromatic ring A (Supporting information SF2). 2D ROESY
spectrum reveals that this peak is correlatedwith the protons of the
alkyl chain H6, H7, and H8 (Supporting information SF3). Similarly
H100 showed ROE with the doublet at 7.04 ppm attributed to the
protons 130, 150 and 180 (Supporting information SF2). The 2D DQF-
COSY experiment conﬁrmed the proposed assignment (Supporting
information SF2). The doublet resonating at 6.86 ppm and assigned
Scheme 3. Reagents and conditions: (a) NXS (X ¼ Cl, Br, I), DMF 0 C/ rt; (b) 16ce
e/ 17cee: 6a, K2CO3, 18-crown-6, THF, reﬂux, 12 h and 16cee/ 18cee: 6b, KOH, 18-
crown-6, Tol, 80 C, 12 h; (c) 30% TFA in CH2Cl2, Et3SiH, rt, 1 h; (d) 37% formalin, dii-
sopropylethylamine, DMF, 80 C, 1 h.
Scheme 5. Reagents and conditions: (a) 29/ 30: 6a, K2CO3, 18-crown-6, THF, reﬂux,
12 h then 30% TFA in CH2Cl2, Et3SiH, rt, 1 h; 29/ 31: 6b, KOH, 18-crown-6, Tol, 80 C,
12 h then 30% TFA in CH2Cl2, Et3SiH, rt, 1 h.
G. Agelis et al. / European Journal of Medicinal Chemistry 62 (2013) 352e370356to 120 and 160 protons is correlated through coupling with the
doublet at 7.04 ppm. Such correlation is evident also with Losartan
molecule that contains biphenyltetrazole segment [32]. As the
integration of the doublet shows the existence of three protons, the
other one is assigned to H180. This is because H180 shows correla-
tion with the triplet peak resonating at 7.25 ppm and assigned to
H190. Consequently, H190 is correlated with multiplet at 7.31 ppm,
assigned to H200, which in turn is correlating with the doublet peak
at 7.55 ppm assigned to H210. The doublet at 7.55 ppm is integrated
to two protons assigned to 21, 210. This is in accordance with results
obtained with Losartan [30]. In addition, these protons areScheme 4. Reagents and conditions: (a) 5b / 25: 6a, K2CO3, DMF, rt, 8 h and
5b/ 26: 6b, K2CO3, DMF, rt, 8 h; (b) 30% TFA in CH2Cl2, Et3SiH, rt, 1 h.expected to be the most magnetically deshielded ones, because
they are close to the tetrazole ring. Apparently, the protons of the
two B and B0 rings have identical or close chemical shifts since they
are far away from the butyl chain that differentiates mainly the
environment of aromatic protons of the A and A0 rings.
The broad singlet at 6.99 ppm has no coupling through bond
correlation. 2D ROESY experiment shows that this peak is corre-
lated through space with H100 and with the protons of the alkyl
chain H6, H7, and H8 (Supporting information SF2 and SF3). This
peak is attributed to H5 of imidazole ring. The two different pat-
terns of biphenyl rings are observed in our previous studies using
commercial and synthetic ARBs. In Losartan [32], Valsartan [33] and
Eprosartan [34] the A ring shows clearly the doublet of doublet
pattern common for 1,4 bis-substituted aromatic compounds.
However, in the synthetic analog V8 a singlet peak is observed that
is attributed to the same ring [17,35]. It is obvious that the equiv-
alency of the protons depends on the environment that surrounds
biphenyltetrazole ring. A small peak at 8.47 ppm as a remaining
peak is assigned to H2. It is the most downﬁeld peak, which can be
explained with the position of H2 between two nitrogens.
2.3. Docking studies of analog 12b at the binding site of AT1
The synthesis of 12b and its derivatives has been based on
docking studies. The docking studies of 12b at AT1 and its in-
teractions with the amino acids of the active site are of particular
interest. Fig. 3 illustrates the best binding pose of 12b at the binding
site of AT1 (DG ¼ 16.21 kcal/mol) with the hydrophilic and hy-
drophobic areas around the molecule. The two biphenyl moieties
point to the widely extended hydrophobic area, whereas the hy-
drophilic area mainly surrounds the imidazole ring and is less
extend around the tetrazole.
Docking calculations using the same program and protocol have
pointed out the best binding pose of Losartan at the active site [17].
In comparison to 12b, Losartan is anchored to the binding site with
a lower binding afﬁnity (DG ¼12.30 kcal/mol) reﬂecting its lower
potency.
In Fig. 4, the superimposition of the best binding poses of 12b
and Losartan is depicted. Both ligands show similar orientation at
the binding site of AT1 except the biphenyl moiety tetrazole (see A0 ,
B0 rings) of 12b which has no equivalent groups. Interestingly, this
additional lipophilic part resides in a lipophilic cavity surrounded
by the amino acids Leu112, Ala181, Phe182, Ile288, Ala291. These
hydrophobic interactions are responsible for the enhanced binding
afﬁnity of 12b in comparison to Losartan. It is this ability of 12b to
reside in an extra cavity that triggered our interest for synthesizing
new drugs having a variety of activity. This drug molecule has
resulted after tryingmanually various derivative compounds which
could ﬁt the extra cavity. 12b has been suggested by the synthetic
group as the drug lead bearing the technognosy of the synthetic
Fig. 2. 1H NMR spectrum of analog 12b in D2O solvent divided into six regions for better representation, recorded on a Varian INOVA 800MHz spectrometer at a temperature of 25 C.
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derivatives shows that collaboration of the medicinal chemists and
computational chemists can lead to new ideas and to the rational
design of new classes of molecules with optimized biological ac-
tivity, taking into account pharmacophore orientation and charges.
2.4. Molecular dynamics (MD) of 12b at the binding site of AT1
It has been postulated that the molecular basis of AT1 anti-
hypertensive action can be interpreted by a two-step model. In the
ﬁrst step, the ARB is incorporated into the membrane bilayer
through the lipidewater interface and secondly laterally diffuses to
reach the binding site of the AT1 receptor in order to exert itsbiological activity [36e38]. For this reason, we have studied not
only the interaction of 12b at the binding site of AT1 receptor but
also its incorporation into plasma membrane.
Before starting the analysis of our results obtained by the MD
simulation, a graphical representation of the simulated system is
provided in Fig. 5(a) where 12b (black color) included in the inte-
rior of the bilayer (dipalmitoyl phospatidylcholine (DPPC): green
color). Fig. 5(b) and (c) depicts the most preferable conformations
of 12b in decreasing order as obtained from a clustering algorithm
available, which is available in the UCSF Chimera software [39]. As
already mentioned, 12b was initially placed into the water phase
and during the course of the simulation penetrated into the interior
of the bilayer. Themass density proﬁles of all components along the
Table 1
1H NMR (800 MHz) chemical shift assignments of 12b in D2O solution at 25 C.
Hydrogen Chemical
shift (ppm)
No. of
hydrogens
Multiplicity
9 0.54 3 t
8 0.97 2 m
7 1.07 2 m
6 2.16 2 t
10 5.06 2 s
100 5.13 2 s
12, 13, 15, 16 6.85 4 bs
120 , 160 6.86 2 d
18 6.97 1 d
5 6.99 1 s
130 and 150 , 180 7.04 3 d
19 7.21 1 t
190 7.25 1 t
20, 200 7.31 2 m
21, 210 7.55 2 d
2 8.47 1 s
(a)
G. Agelis et al. / European Journal of Medicinal Chemistry 62 (2013) 352e370358Z-axis are provided in Fig. 6; it is clearly seen that 12b under study
is found inside the bilayer (red curve). The peak of its distribution is
nearly 1.1 nm far from the center of the bilayer which is deﬁned as
the minimum of the DPPC distribution (blue color). AnotherFig. 3. Binding mode of analog 12b at the binding site of AT1 receptor. The hydro-
phobic region of the binding site is shown in yellow, and the hydrophilic site that
surrounds it by a 6 A radius is shown in blue. The Phe 249 (red color) is situated be-
tween the two biphenyltetrazole moieties of analog 12b. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
12b
Losartan
Fig. 4. Superimposition of Losartan (blue) and analog 12b (brown). (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
(b)
(c)
Fig. 5. (a) A graphical representation of the simulated system. (b), (c) Most preferable
conformations of analog 12b in the DPPC bilayer.interesting observation is that 12b is found in a depth that permits
an interaction with some water molecules as seen by the intercept
of the distribution of water (black curve) and drug. A comple-
mentary view is given by Fig. 7, in which the distance between
Fig. 6. Mass density proﬁles along the Z-axis of all components, i.e. water, DPPC and
analog 12b. Fig. 8. PMF (along the Z-axis) of analog 12b from water to DPPC phase.
G. Agelis et al. / European Journal of Medicinal Chemistry 62 (2013) 352e370 359DPPC and drug centers of mass is monitored over the last 40 ns of
the MD simulation. The zero in the aforementioned diagram cor-
responds to the center of bilayer. In order to give a clearer picture of
the simulated system, the average distance of phosphorous atoms
(DPPC molecules) in both leaﬂets is depicted as well, indicating
a stable membrane with a thickness around 3.8 nm. It may also be
concluded that the drug ﬂuctuates around a distance of 1.1 nm from
the bilayer center. However, it does not move signiﬁcantly and
therefore there is no tendency for crossing events, i.e. the move of
a host molecule from one leaﬂet to the other through the middle of
the bilayer.
The potential of mean force (PMF) of 12b from water to lipid
phase is depicted in Fig. 8, in which the zero at the abscissa cor-
responds to the bilayer center while remote there is purewater. The
position of minimum is about 1 nm far from the bilayer center and
it is compatible to the position found by the MD simulation with
12b initially placed in the aqueous phase. Another interesting
observation is the high energy barrier (41 kJ mol1) that 12b has to
overcome so as to move from one leaﬂet to the other through the
middle of the bilayer. Besides, the free energy for partitioning into
the membrane was estimated by the difference of PMF at the water
phase (large distances) and at the location of the minimum. This
value is approximately equal to 81 kJ mol1.
Having deﬁned the preferred position of 12b in the membrane
from the mass density proﬁles and the PMF, we analyzed theFig. 7. Distance between analog 12b and bilayer centers of mass. This plot is over the
last 40 ns of the simulation. No crossing events were observed.interaction of this drug with DPPC and water molecules in terms of
hydrogen bonding. To this end, a GROMACS tool was applied which
makes use of standard geometrical criteria such as distance be-
tween acceptor and donor (<0.35 nm) and the angle among
acceptorehydrogenedonor (<30). The average number of hydro-
gen bonds of 12bwith DPPC and the penetrated water molecules is
1.366 and 1.519, respectively, showing that indeed there is a sig-
niﬁcant interaction with these components. In particular, DPPC
oxygen atoms participate in a hydrogen-bond network with two
nitrogen atoms of 12b which are indicated by two arrows in
Fig. 5(b). An additional conﬁrmation of the previous observation is
provided in Fig. 9 by the fully overlapping density proﬁles of oxygen
(DPPC) and nitrogen atoms (12b).2.5. HOMO and LUMO quantum chemical calculations
Table 2 summarizes the results of HOMO and LUMO levels of the
compounds studies. Based on these results, binding afﬁnities and
the in vitro ANGII antagonist properties, several remarks can be
made. First of all, inclusion of halogens (Br, Cl, and I) in R1 position
reduced HOMO values as expected. As already mentioned HOMO
energy values decrease with the presence of electron withdrawing
groups (EWGs) such as halogens. A decrease in in vitro binding
afﬁnity as determined in radioligand binding studies for com-
pounds 19c and 19d was also reported. The inclusion of a smallFig. 9. Density proﬁles along Z-axis of DPPC oxygens and analog 12b nitrogens. The
points of black curve have been multiplied by 10 for visualization purposes.
Table 2
HOMO and LUMO energies, binding afﬁnity expressed as elogIC50 values and clas-
siﬁcation of synthesized analogs according to the afﬁnity.
Compd HOMO (eV) LUMO (eV) Binding afﬁnity
elogIC50
Classiﬁcation
11 0.3185 0.1449 9.46  0.44 High afﬁnity
12a 0.26218 0.13175 9.04  0.38 High afﬁnity
12b 0.28058 0.1382 8.54  0.18 High afﬁnity
14 0.31844 0.14207 8.37  0.15 High afﬁnity
19c 0.30837 0.14742 6.08  0.14 Low afﬁnity
19d 0.30956 0.14558 6.15  0.22 Low afﬁnity
23c 0.31631 0.14252 5.19  0.42 Low afﬁnity
23d 0.31508 0.13845 7.37  0.29 High afﬁnity
27 0.32167 0.13413 5.77  0.46 Low afﬁnity
30 0.31916 0.14134 6.38  0.02 Low afﬁnity
13 0.33018 0.13951 6.48  0.10 Low afﬁnity
15 0.33136 0.15484 6.30  0.08 Low afﬁnity
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change HOMO and LUMO values but resulted also in a reduced
binding afﬁnity. The afﬁnity was further reduced when halogens
were also included in the R1 position (23c, 23d) as expressed in
in vitro activity (pA2). Inclusion of K and Na (12a and 12b) sig-
niﬁcantly reduced HOMO values and a decrease in binding afﬁnity
(elogIC50) was also reported. A switch of the substituents in R2 and
R3 position for 11 and 27, 19c and 30 also resulted in a decreased
activity while HOMO increased and LUMO decreased.
We have further explored the HOMO LUMO energies by devel-
oping a simple Decision Tree with the primary purpose of discrim-
inating compounds into two categories, lowafﬁnityandhigh afﬁnity,
(threshold elogIC50 < 6.48). HOMO and LUMO values were used as
inputvariables for thedevelopmentof theDecisionTree (Fig.10) [40].
The visual inspection of the Decision Tree helps in the analysis and
interpretation of the structural data, the existence of clusters and
outliers, the relationship between samples and the inﬂuence of eachFig. 10. Graphical representation of the Decision Tree.
Fig. 11. HOMO and LUMOvariable (HOMO & LUMO). The accuracy of the Decision Tree is 92%.
The graphical representation of the Decision Tree for the data set is
presented in Fig.11. According to theDecisionTree, thedesignof new
molecules as ARBs can been accomplishedbyhighHOMOand LUMO
energy values. More speciﬁcally, in the case of HOMO values are
greater than 0.31916 eV and LUMO greater than 0.14252, the
compounds exert high binding afﬁnity to the receptor. HOMO and
LUMO ﬁelds are graphically depicted in Fig. 11 for 11.
2.6. Pharmacological characterization and SAR
In order to pharmacologically characterize the synthesized
analogs, we determined their binding afﬁnities (elogIC50) for the
human AT1 receptor in radioligand competition binding assay
(Table 3, Fig. 12(a) and (b)), as well as their ability to antagonize the
activity of ANGII in the rat uterus in vitro test (pA2) of the high
afﬁnity compounds (elogIC50  6.50) using Losartan as a reference
compound (Table 3). Interestingly, the introduction of an addi-
tional biphenyltetrazole moiety on the 4(5)-butylimidazole led
to the N,N0-bis-substituted imidazolium salt 11, which is bound to
AT1 receptor with higher afﬁnity (elogIC50 ¼ 9.46) than Losartan
(elogIC50 ¼ 8.25) (Table 3, Fig. 12). Furthermore, the water soluble
potassium (elogIC50 ¼ 9.04) and sodium (elogIC50 ¼ 8.54) salts of
compound 11 (12a and 12b, respectively) showed slightly
higher binding afﬁnities compared to Losartan (elogIC50 ¼ 8.25)
(Table 3, Fig. 12). Similar to binding afﬁnities, the potency of 12b
(pA2 ¼ 8.45) to antagonize the activity of ANGII was higher com-
pared to Losartan (pA2 ¼ 8.25). Acquisition of high binding afﬁnity
and potency has also been achieved by the introduction of the
hydroxymethyl group at the C-2, resulting in 14 (elogIC50 ¼ 8.37,
pA2 ¼ 8.58) (Table 3, Fig. 12). Replacement of the tetrazole with
the bioisostere carboxy group, thus resulting in 13 and 15 sig-
niﬁcantly decreased binding afﬁnity (Fig. 12) in line with previous
studies in which tetrazole is a superior non-classical isostere of
carboxylate [10,19]. More importantly, the halogenated analogs
19c, 19d, 23c, 23d (Table 3, Fig. 12) showed remarkable drop in
binding afﬁnity in contrast to the halogenated series of
Losartan which retained afﬁnity [10] indicating the ambiguous
function of substituents at C-4 of imidazole [19]. Interestingly,
the bis-alkylation of 2-butylimidazole and 2-butyl-4-chloro-5-
hydroxymethylimidazole, the key precursor in the synthesis
of Losartan, resulted in compounds 27 (elogIC50 ¼ 5.77) and 30 (e
logIC50 ¼ 6.38) (Table 3, Fig. 12) displaying dramatic loss of binding
afﬁnity compared to 11, in which the n-butyl group at the C-5 is
exposed, thus enhancing binding to the receptor. These results
suggested that the position of the n-butyl group plays a signiﬁcant
role in their interaction with the AT1 receptor.orbitals of analog 11.
Table 3
Biological activity of synthesized analogs.
Compd R1 R2 R3 R Binding afﬁnity
elogIC50
Uterotonic activity
in vitro pA2
11 H Bu H H 9.46  0.44
12a H Bu H K 9.04  0.38
12b H Bu H Na 8.54  0.18 8.45  0.39
14 H Bu CH2OH H 8.37  0.15 8.58  0.39
19c Cl Bu H H 6.08  0.14
19d Br Bu H H 6.15  0.22
23c Cl Bu CH2OH H 5.19  0.42
23d Br Bu CH2OH H 7.37  0.29 7.13  0.13
27 H H Bu H 5.77  0.46
30 Cl CH2OH Bu H 6.38  0.02
Losartan 8.25  0.06 8.25  0.13
13 H Bu H H 6.48  0.10
15 H Bu CH2OH H 6.30  0.08
Fig. 12. Competition binding isotherms of ANGII analogs to human AT1 receptor.
Competition of [125I-Sar1-Ile8] ANGII speciﬁc binding by increasing concentrations of
ANGII analogs was performed as described under “materials and methods” using
membranes from HEK 293 cells stably expressing the human AT1 receptor. The means
and S.E. are shown from 2 to 4 different experiments. The data were ﬁt to a one-site
competition model by nonlinear regression and the elogIC50 values were deter-
mined as described under “materials and methods”. (a) Losartan and analogs 11, 12a,
12b, 13, 14, 15, 27 and 30 (b) Losartan and analogs 19c, 19d, 23c and 23d.
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The present study refers to the design and syntheses of bis-
alkylated 4(5)-butylimidazole analogs as potent ARBs. In partic-
ular, a rational design was performed to synthesize a series of N,N0-
symmetrically bis-substituted imidazole analogs bearing at the N-1
and N-3 two biphenylmethylmoieties ortho substituted either with
tetrazole or carboxylate functional groups. This work describes for
the ﬁrst time potent N,N0-bis-alkylated analogs in contrast to the
marketed ARBs, which their heterocyclic core is monoalkylated.
Furthermore, we elaborated general synthetic methodology for the
assembly of the n-butyl group onto the imidazole ring via the
Wittig reaction as well as the bis-alkylation of the N-1 and N-3 of
4(5)-butylimidazole and 2-butylimidazole with the biphe-
nylmethyl moiety. A remarkably efﬁcient approach was also
adopted for the introduction of the hydroxymethyl group at the C-2
position, as we have previously shown [19]. The SAR studies
demonstrated the importance of the nature and the position of
pharmacophores. In particular, the presence of two anionic tetra-
zole groups along with the lipophilic n-butyl group at the C-5 led to
the potent analogs 11 and its water soluble salts 12a and 12b. The
introduction of the electronegative hydroxymethyl group at the C-2
(analog 14) led to acquisition of afﬁnity and potency, while the
presence of a halogen atom at the C-4 of the imidazole ring (analogs
19cee and 23cee) led to an essential decrease in afﬁnity. Therefore,the presence of two tetrazole rings seems to be optimal for high
afﬁnity in contrast to the carboxy group (analogs 13, 15) which
represents poor bioisostere for the tetrazole group, since these
analogs showed remarkably low afﬁnity. The position of the n-butyl
group plays a signiﬁcant role, since reorientation from the 4- (an-
alogs 11, 12a, 12b) to the 2-position (27, 30) of the imidazole ring
resulted in a sharp drop of binding afﬁnity. This dramatic loss of
activity may be explained by the concealment of the n-butyl group
between the two biphenyltetrazole moieties.
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synthetic analog 12b. Its higher afﬁnity and potency to antagonize
ANGII compared to Losartan can be explained by docking studies
which demonstrated an additional hydrophobic cavity. MD calcu-
lations on lipid bilayers showed that this molecule is incorporated
at the interface and exerts a network of interactions with polar
region. Thus, this molecule does not only interact with the same
binding site as other sartans but also acts through lipid bilayer at
the same topographical location [41e44]. Particularly, it anchors at
the interface as other sartans where exerts its amphiphilic in-
teractions both with the polar region and upper hydrophobic seg-
ments of the phospholipid bilayers. Biophysical studies are in
progress to provide more information on this issue. Another
important ﬁnding from these studies is the critical role of the ori-
entation of the lipophilic n-butyl group. The highly hydrophobic
residues of receptor that surround this group and interact through
van der Waals interactions can explain its orientation signiﬁcance.
4. Experimental section
4.1. Chemistry
4.1.1. General
Starting materials were obtained by Aldrich and used as
received. All reactions involving air sensitive reagents were per-
formed under Ar atmosphere using syringe-septum cap techniques.
Melting points were determined with a Stuart SMP 10 apparatus
and are uncorrected. Hydrogenation reaction was carried out in
a Parr Hydrogenation Apparatus equipped with a 4 L Hydrogen
tank. 1H NMR and 13C NMR spectra were recorded on a Bruker
Avance DPX spectrometer at 400.13 MHz and 161.76 MHz, respec-
tively. Chemical shifts are reported in units, parts per million (ppm)
downﬁeld from tetramethylsilane (TMS) and coupling constants (J)
are given in Hertz (Hz). The 2D DQF-COSY and ROESY NMR spectra
were recorded on a Varian DirectDrive 800 MHz spectrometer at
25 C. 2 mg of 12b were dissolved in 0.7 mL of D2O. Experiments
were recorded in the phase-sensitive mode using the pulse se-
quences in the Varian library of pulse programs. Spectra were ac-
quired with a spectral width of 8012 Hz, 4096 data points in t2, 4e
32 scans, 512 complex points in t1, and a relaxation delay of 1.5 s.
The mixing time in 2D ROESY was 75 ms. HPLC analysis was per-
formed on an Alliance Waters 2695 equipped with a Waters 2996
Photodiode Array Detector UVevis, using the XBridge C18 column
(4.6  150 mm, 3.5 mm) as stationary phase and a gradient of H2O/
MeCN both containing 0.08% TFA as mobile phase. Electrospray-
ionization mass spectra (ESI-MS) were obtained on a UPLC (ultra
performance liquid chromatography) equipped with SQ detector
Acquity by Waters. All reactions were carried out in anhydrous
solvents. Analytical TLC was performed on silica gel 60 F254 plates
(Merck, Germany) and visualized by UV irradiation and iodine.
4.2. Synthesis of 4(5)-butylimidazole (5a)
4.2.1. 1-Trityl-imidazole-4-carboxaldehyde (2a)
Prepared from imidazole (1) as starting material according to
the literature method [20,21]. Data are consistent with literature. Rf
0.53 (EtOAc/Hex 4:1); tR 11.59 min (30% MeCN / 100% MeCN in
30 min); 1H NMR (400 MHz, CDCl3): d 9.88 (s, 1H), 7.61 (d, 1H,
J ¼ 1.3 Hz), 7.53 (s, 1H, J ¼ 1.3 Hz), 7.38e7.36 (m, 9H), 7.12e7.10 (m,
6H); 13C NMR (160 MHz, CDCl3): d 186.51, 141.47, 140.79, 140.56,
129.60, 128.49, 128.34, 127.88, 126.72.
4.2.2. (Z)-1-Trityl-4-(but-1-enyl)imidazole (3a)
A suspension of 2a (0.50 g, 1.48 mmol), propyl triphenylphos-
phoniumbromide (0.63 g,1.63mmol) and NaH (powered 95%, 0.05 g,2.22 mmol) in anhydrous THF (8 mL), was stirred at rt for 8 h under
Ar atmosphere. Then, the reaction mixture was quenched with
saturated aqueousNaHCO3 (5mL) solution and extractedwith CH2Cl2
(3  15 mL). The organic layer was washed with H2O (1  10 mL),
dried over Na2SO4 and concentrated in vacuo. The residue was pu-
riﬁed by ﬂash column chromatography (silica gel, EtOAc/Hex 1:1) to
furnish the Z-3 isomer (0.44 g) which is the sole isolated product.
Yield: 81%; Rf 0.63 (EtOAc/Hex 4:1); tR 12.42min (30%MeCN/ 100%
MeCN in 30min); ESI-MS (m/z): 123.18 [Mþ H], 243.26 [Tr]; 1H NMR
(400 MHz, CDCl3): d 7.64 (br s, 1H), 7.36e7.35 (m, 9H), 7.16e7.13 (m,
6H), 6.75 (br s, 1H), 6.25 (dt, 1H, J ¼ 1.5, 11.6 Hz), 5.60 (dt, 1H, J ¼ 7.5,
11.6 Hz), 2.28 (quint d, 2H, J ¼ 1.7, 7.5 Hz), 1.00 (t, 3H, J ¼ 7.5 Hz); 13C
NMR (160 MHz, CDCl3): d 141.70, 137.64, 137.15, 134.53, 129.66,
128.29, 128.18, 120.20, 119.00, 76.03, 22.55, 13.79.
4.2.3. 1-Trityl-4-butylimidazole (4a)
A solution of 3a (0.30 g, 0.82 mmol) in anhydrousMeOH (10mL)
was transferred in a hydrogenation ﬂask and Pd/C (10% wt/wt,
0.04 g, 0.04 mmol) was added. The reaction mixture was allowed to
proceed at rt, under a H2 atmosphere at a pressure of 3 bar (Parr
hydrogenator apparatus) for 2 h. Then, the catalyst was ﬁltered
through a pad of Celite and washed with MeOH. The combined
ﬁltrates were concentrated in vacuo to furnish 4a as a white foam
(0.28 g), which was directly used without further puriﬁcation.
Yield: 92%; Rf 0.53 (EtOAc/Hex 4:1); tR 13.15 min (30%
MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 367.50 [M þ H],
243.38 [Tr]; 1H NMR (400 MHz, CDCl3): d 7.64 (s, 1H), 7.33e7.31 (m,
10H), 7.15e7.13 (m, 6H), 6.50 (s, 1H), 2.53 (t, 2H, J ¼ 7.5 Hz), 1.59 (q,
2H, J ¼ 7.5 Hz), 1.33 (sext, 2H, J ¼ 7.5 Hz), 0.91 (t, 3H, J ¼ 7.5 Hz); 13C
NMR (160 MHz, CDCl3): d 148.81, 142.63, 142.12, 138.16, 129.79,
127.93, 127.89, 127.85, 127.15, 117.60, 74.99, 31.48, 28.17, 22.41, 13.91.
4.2.4. 4(5)-Butylimidazole (5a)
Compound 4a (0.20 g, 0.55 mmol) was dissolved in a solution of
20% TFA in CH2Cl2 (2 mL) and then Et3SiH (0.09 mL, 0.55 mmol) was
added as scavenger. The resulting solution was stirred at rt for 1 h
and concentrated in vacuo. Precipitation from Et2O furnished the
TFA salt of 5a as an amorphous powder. The TFA salt was neutralized
by treatment with saturated aqueous NaHCO3 solution for 30min at
rt and extracted with CH2Cl2 (3  10 mL). The organic phase was
dried over Na2SO4, ﬁltered and concentrated in vacuo to afford 5a
(0.06 g) as a yellow solid. Yield: 87%; m.p. 45e47 C; Rf 0.60 (CHCl3/
MeOH 9:1); tR 6.82 min (5% MeCN/ 100% MeCN in 30 min); ESI-
MS (m/z): 125.19 [M þ H]; 1H NMR (400 MHz, CD3OD): d 7.54 (s,
1H), 6.74 (s, 1H), 2.59 (t, 2H, J ¼ 7.2 Hz), 1.62 (quint, 2H, J ¼ 7.2 Hz),
1.38 (sext, 2H, J¼ 7.2 Hz), 0.97 (t, 3H, J¼ 7.2 Hz); 13C NMR (160MHz,
CD3OD): d 136.83, 134.47, 117.28, 31.76, 26.04, 22.28, 13.17.4.3. Synthesis of 2-butylimidazole (5b), method A
4.3.1. 1-[(N,N-Dimethylamino)methyl]imidazole (2b)
Prepared from imidazole (1) according to the literature method
[23]. Data were consistent with literature. Rf 0.44 (CHCl3/MeOH
9:1); tR 2.41 min (5% MeCN/ 100% MeCN in 30 min); ESI-MS (m/
z): 126.58 [MþH]; 1H NMR (400MHz, CDCl3): d 7.44 (s, 1H), 7.01 (s,
1H), 6.90 (s, 1H), 4.61 (s, 2H), 2.23 (s, 6H); 13C NMR (160 MHz,
CDCl3): d 137.63, 129.08, 119.74, 69.25, 41.49.
4.3.2. 2-Butylimidazole (5b)
To a solution of 2b (0.25 g, 2 mmol) in anhydrous THF (10 mL)
under Ar atmosphere was added n-BuLi (1.6 M in hexanes, 1.37 mL,
2.20 mmol) dropwise via a syringe at 78 C. After 30 min, DMPU
(0.48 mL, 4.0 mmol) was added at 70 C and stirred for additional
30 min before n-BuI (0.27 mL, 2.40 mmol) was added at78 C. The
reaction mixture was allowed to warm to rt over a period of 16 h.
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removed and the resulting mixture was neutralized with saturated
aqueousNaHCO3 solution and extractedwith CH2Cl2 (315mL) The
organic phase was dried over Na2SO4 and concentrated in vacuo to
furnish 5b as a pale yellow oil (0.21 g). Data were consistent with
literature. Yield: 85%; Rf 0.54 (CHCl3/MeOH 9:1) tR 5.52 min (5%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 125.17 [M þ H]; 1H
NMR (400 MHz, CDCl3): d 6.87 (s, 2H), 2.68 (t, 2H, J ¼ 7.5 Hz), 1.67
(quint, 2H, J¼ 7.5Hz),1.34 (sext, 2H, J¼ 7.5Hz), 0.93 (t, 3H, J¼7.5Hz);
13CNMR(160MHz,CDCl3): d148.97,120.84, 30.81, 27.64, 22.20,12.95.4.4. Synthesis of 2-butylimidazole (5b), method B
4.4.1. 1-(N,N-Dimethylsulfamoyl)imidazole-2-carboxaldehyde (2c)
Prepared from imidazole (1) according to the literature method
[25]. Data are consistent with literature. Rf 0.20 (EtOAc/Hex 7:3); tR
5.00 min (5% MeCN / 100% MeCN in 30 min); ESI-MS (m/z):
204.29 [M þ H]þ; 1H NMR (400 MHz, CDCl3): d 9.93 (s, 1H), 7.58 (d,
1H, J ¼ 1.5 Hz), 7.30 (d, 1H, J ¼ 1.5 Hz), 3.00 (s, 6H); 13C NMR
(160 MHz, CDCl3): d 179.09, 143.45, 130.16, 125.87, 38.56.
4.4.2. 1-(N,N-Dimethylsulfamoyl)-2-(but-1-enyl)imidazole (3c)
To a stirred suspension of propyl triphenylphosphonium bro-
mide (1.43 g, 3.72 mmol) and anhydrous t-amyl alcohol (0.45 mL,
4.09 mmol) in anhydrous THF (14 mL) was added NaH (powdered
95%, 0.10 g, 4.09 mmol) at 0 C under Ar atmosphere and stirred at
rt for 2 h. To the resulting yellow phosphorous ylide was added
a solution of 2c (0.38 g, 1.86 mmol) in anhydrous THF (2 mL)
dropwise at 0 C. The mixture was stirred at rt over a period of 8 h
before being quenched with saturated aqueous NaHCO3 solution
and extracted with CH2Cl2 (3  20 mL). The organic layer was
washed with H2O (2  10 mL), dried over Na2SO4 and concentrated
in vacuo. The residuewas puriﬁed by ﬂash column chromatography
(silica gel, EtOAc/Hex 3:2) to afford the pure Z- and E-9 isomers as
yellow oils (0.26 g and 0.10 g, respectively). Z-Isomer: yield: 62%; Rf
0.46 (EtOAc/Hex 7:3); tR 10.08 min (5% MeCN / 100% MeCN in
30 min); ESI-MS (m/z): 230.33 [M þ H]þ; 1H NMR (400 MHz,
CDCl3): d 7.27 (d, 1H, J ¼ 1.3 Hz), 7.07 (d, 1H, J¼ 1.3 Hz), 6.66 (dt, 1H,
J¼ 1.3, 11.7 Hz), 5.98 (dt, 1H, J¼ 7.4, 11.7 Hz), 2.85 (s, 6H), 2.70 (quint
d, 2H, J ¼ 1.9, 7.4 Hz), 1.08 (t, 3H, J ¼ 7.4 Hz); 13C NMR (160 MHz,
CDCl3): d 145.14, 142.46, 128.00, 119.69, 114.76, 38.37, 22.86, 13.73.
E-Isomer: yield: 24%; Rf 0.25 (EtOAc/Hex 7:3); tR 10.26 min (5%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 230.29 [M þ H]þ;
1H NMR (400 MHz, CDCl3): d 7.25 (d, 1H, J ¼ 1.5 Hz), 6.99 (s, 1H,
J ¼ 1.5 Hz), 6.90 (dt, 1H, J ¼ 7.4, 15.6 Hz), 6.78 (d, 1H, J ¼ 15.6 Hz),
2.85 (s, 6H), 2.82 (quint d, 2H, J ¼ 1.4, 7.4 Hz), 1.10 (t, 3H, J¼ 7.4 Hz);
13C NMR (160 MHz, CDCl3): d 146.38, 141.41, 128.06, 119.89, 115.86,
38.33, 26.00, 12.91.
4.4.3. 1-(N,N-Dimethylsulfamoyl)-2-butylimidazole (4c)
Compound 4c was prepared in an analogous manner to that
described for 4a. A mixture of the isolated Z- and E- was subjected
to catalytic hydrogenation. Yield: 90%; Rf 0.44 (CHCl3/MeOH 95:5);
tR 10.45 min (5% MeCN/ 100% MeCN in 30 min); ESI-MS (m/z):
231.97 [M þ H]þ; 1H NMR (400 MHz, CD3OD): d 7.38 (d, 1H,
J ¼ 1.4 Hz), 6.64 (d, 1H, J ¼ 1.4 Hz), 3.30 (s, 6H), 2.95 (t, 2H,
J¼ 7.6 Hz),1.73 (quint, 2H, J¼ 7.6 Hz),1.40 (sext, 2H, J¼ 7.6 Hz), 0.95
(t, 3H, J ¼ 7.6 Hz); 13C NMR (160 MHz, CD3OD): d 144.16, 126.16,
119.66, 37.16, 30.08, 27.68, 21.97, 12.66.
4.4.4. 2-Butylimidazole (5b)
A solution of 4c (0.20 g, 0.86 mmol) in THF (2 mL) was reﬂuxed
with 1.5 N HCl (3 mL) for 2 h and then cooled. After neutralization
by addition of saturated aqueous NaHCO3 solution, the solvent was
concentrated in vacuo to give a residue, which was extracted withCH2Cl2 (3  10 mL). The combined organic extracts were washed
with brine, dried over Na2SO4 and concentrated in vacuo to afford 7
as a pale yellow oil (0.09 g, 86%).
4.5. General procedure 1: bis-alkylation of 4(5)-butylimidazole (5a)
4.5.1. 4-Butyl-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]biphenyl-4-yl]
methyl}imidazolium bromide (7)
To a solution of 4(5)-butylimidazole (5a) (1.00 g, 8.05 mmol) in
anhydrous DMF (30 mL) were sequentially added K2CO3 (2.22 g,
16.10 mmol) and the alkylating agent 6a (10.31 g, 18.52 mmol)
under Ar atmosphere and stirred at rt for 8 h. Then, the mixture
was diluted with CH2Cl2 (90 mL), washed with H2O (3  50 mL),
the organic phase was dried over Na2SO4, ﬁltered and concentrated
in vacuo. The resulting residue was precipitated from cold Et2O to
afford 7 as a white solid. Yield 78%; Rf 0.45 (CHCl3/MeOH, 9:1); tR
15.93 min (70% MeCN / 100% MeCN in 30 min); ESI-MS (m/z):
1078.56 [M  Br], 243.17 [Tr]; 1H NMR (400 MHz, CDCl3): d 11.03 (s,
1H), 7.90e7.84 (m, 2H), 7.43e7.30 (m, 5H), 7.30e7.09 (m, 25H),
6.88e6.83 (m, 14H), 6.46 (s, 1H), 5.31 (s, 4H), 2.20 (t, 2H, J ¼ 7.5 Hz),
1.26e1.09 (m, 4H), 0.72 (t, 3H, J ¼ 7.5 Hz).
4.5.2. 4-Butyl-N,N0-bis{[20-(tert-butoxycarbonyl)biphenyl-4-yl]
methyl}imidazolium bromide (8)
The same procedure was employed for the alkylation of 5a by
treatment with the alkylating agent 6b. Yield 82%; Rf 0.32 (CHCl3/
MeOH 9:1); tR 9.59 min (60% MeCN/ 100% MeCN in 30 min); ESI-
MS (m/z): 657.63 [M  Br]; 1H NMR (400 MHz, CDCl3): d 11.02 (s,
1H), 7.80 (dd, 2H, J ¼ 7.5 Hz, J ¼ 1.2 Hz), 7.47 (t, 2H, J ¼ 7.6 Hz), 7.40
(t, 2H, J ¼ 7.6 Hz), 7.35e7.22 (m, 8H), 7.11 (d, 2H, J ¼ 7.5 Hz), 6.79 (s,
1H), 5.56 (s, 2H), 5.50 (s, 2H), 2.43 (t, 2H, J¼ 7.4 Hz), 1.44 (quint, 2H,
J ¼ 7.4 Hz), 1.30 (sext, 2H, J ¼ 7.4 Hz), 1.21 (s, 18H), 0.82 (t, 3H,
J ¼ 7.4 Hz).
4.6. General procedure 2: hydroxymethylation at C-2 position of 7
4.6.1. 4-Butyl-2-hydroxymethyl-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]
biphenyl-4-yl]methyl}imidazolium bromide (9)
In a sealed tube were sequentially added 7 (0.50 g,
0.43 mmol), DMF (1 mL), 37% formalin (0.11 mL, 1.48 mmol) and
diisopropylethylamine (0.51 mL, 3.01 mmol). The resulting mix-
ture was stirred at 80 C until HPLC showed no starting material
left (ca. 1 h). Then, the mixture was diluted with CH2Cl2 (30 mL),
washed with 5% aqueous citric acid (2  10 mL), brine (10 mL),
the organic phase was dried over Na2SO4, ﬁltered and con-
centrated in vacuo. The resulting residue was precipitated from
cold Et2O to afford 9 as a white powder. Yield 84%; Rf 0.36 (CHCl3/
MeOH 9:1); tR 15.32 min (70% MeCN/ 100% MeCN in 30 min);
ESI-MS (m/z): 1108.06 [M  Br]; 1H NMR (400 MHz, CDCl3):
d 7.96e7.93 (m, 2H), 7.50e7.43 (m, 5H), 7.37e7.14 (m, 20H), 7.07
(d, 2H, J ¼ 8.0 Hz), 6.94e6.91 (m, 15H), 6.85 (d, 2H, J ¼ 8.0 Hz),
6.46 (s, 1H), 5.53 (s, 2H), 5.47 (s, 2H), 4.64 (s, 2H), 2.34 (t, 2H,
J ¼ 7.5 Hz), 1.40 (quint, 2H, J ¼ 7.5 Hz), 1.26 (sext, 2H, J ¼ 7.5 Hz),
0.80 (t, 3H, J ¼ 7.5 Hz).
4.6.2. 4-Butyl-2-hydroxymethyl-N,N0-bis{[[20-(tert-butoxycarbonyl)]
biphenyl-4-yl]methyl}imidazolium bromide (10)
The same procedure was employed for the hydroxymethylation
of 8. Yield: 81%; Rf 0.31 (CHCl3/MeOH 9:1); tR 8.91 min (60%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 687.56 [M  Br];
1H NMR (400 MHz, CDCl3): d 7.72 (t, 2H, J ¼ 7.0 Hz), 7.47e7.40 (m,
2H), 7.36e7.17 (m, 10H), 7.04 (d, 2H, J ¼ 8.0 Hz), 6.85 (s, 1H), 5.66
(s, 4H), 4.82 (s, 2H), 2.48 (t, 2H, J ¼ 7.5 Hz), 1.49 (quint, 2H,
J ¼ 7.5 Hz), 1.31 (sext, 2H, J ¼ 7.5 Hz), 1.21 (s, 9H), 1.20 (s, 9H), 0.83
(t, 3H, J ¼ 7.5 Hz).
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4.7.1. 4-Butyl-N,N0-bis{[[20-(2H-tetrazol-5-yl)]biphenyl-4-yl]
methyl}imidazolium bromide (11)
Compound 7 (0.40 g, 0.34 mmol) was dissolved in a solution of
30% TFA (1.2 mL) in CH2Cl2 (2.8 mL) and then Et3SiH (54 mL,
0.34 mmol) was added as a scavenger. The resulting solution was
stirred at rt for 1 h before being concentrated in vacuo. Precipi-
tation from Et2O furnished an amorphous solid, then, dissolved in
CH2Cl2 (20 mL) and the resulting mixture was washed with satu-
rated aqueous NaHCO3 solution (2  5 mL), dried over Na2SO4,
ﬁltered and concentrated in vacuo to furnish 11 as a white solid:
yield 72%; m.p. 201e203 C; Rf 0.35 (CHCl3/MeOH/gl. AcOH,
9:1:0.1); tR 12.35 min (20% MeCN/ 100% MeCN in 30 min); ESI-
MS (m/z): 593.57 [M  Br]; 1H NMR (400 MHz, DMSO-d6): d 9.35
(d, 1H, J ¼ 1.2 Hz), 7.71e7.67 (m, 4H), 7.62 (d, 2H, J ¼ 7.0 Hz), 7.59
(br s, 1H), 7.55 (d, 2H, J ¼ 7.0 Hz), 7.37 (d, 2H, J ¼ 8.1 Hz), 7.25 (d,
2H, J ¼ 8.1 Hz), 7.19e7.16 (m, 4H), 5.45 (s, 2H), 5.41 (s, 2H), 1.44
(quint, 2H, J ¼ 7.5 Hz), 1.28 (sext, 2H, J ¼ 7.5 Hz), 0.94 (t, 3H,
J ¼ 7.5 Hz); 1H NMR (400 MHz, CD3OD): d 9.02 (br s, 1H), 7.71e7.67
(m, 4H), 7.61e7.56 (m, 4H), 7.46 (br s, 1H), 7.36 (d, 2H, J ¼ 8.0 Hz),
7.26e7.20 (m, 6H), 5.40 (s, 2H), 5.38 (s, 2H), 2.57 (t, 2H, J ¼ 7.5 Hz),
1.56 (quint, 2H, J ¼ 7.5 Hz), 1.38 (sext, 2H, J ¼ 7.5 Hz), 0.92 (t, 3H,
J ¼ 7.5 Hz); 13C NMR (160 MHz, DMSO-d6): d 160.54, 160.19, 143.46,
142.99, 142.92, 138.99, 138.29, 136.00, 135.48, 133.30, 133.26,
133.10, 133.02, 132.30, 132.26, 132.22, 132.03, 130.57, 130.47, 130.29,
130.22, 130.12, 129.99, 122.21, 54.46, 51.98, 31.30, 25.27, 24.24,
16.25.
4.8. General procedure 4: conversion to the potassium salt 12a
4.8.1. Bis-potassium salt of 4-butyl-N,N0-bis{[20-(2H-tetrazol-5-yl)]
biphenyl-4-yl]methyl}imidazolium bromide (12a)
To a suspension of 11 (0.20 g, 0.30 mmol) in MeOHeH2O, 1:1
(4 mL) was added KOH (33 mg, 0.60 mmol) and the reaction
mixture was stirred at rt for 5 h. Activated charcoal was added to
the mixture, stirred for 10 min before being ﬁltered through a pad
of Celite. The ﬁltrate was concentrated in vacuo to remove ca. half
the solvent volume. The residue was precipitated with acetone to
afford a white solid. Lyophilization of the resulting solid furnished
the potassium salt 12a as a white foam. Yield 80%; Rf 0.30 (CHCl3/
MeOH/gl. AcOH, 9:1:0.1); tR 12.19 min (20% MeCN/ 100% MeCN
in 30 min); ESI-MS (m/z): 631.23 [(M  K) þ H  Br]; 1H NMR
(400 MHz, CD3OD): d 8.93 (s, 1H), 7.60e7.58 (m, 2H), 7.53e7.50 (m,
2H), 7.47e7.45 (m, 4H), 7.41 (s, 1H), 7.27 (d, 2H, J ¼ 8.0 Hz), 7.21e
7.15 (m, 6H), 5.33 (s, 2H), 5.32 (s, 2H), 2.59 (t, 2H, J ¼ 7.5 Hz), 1.56
(quint, 2H, J ¼ 7.5 Hz), 1.39 (sext, 2H, J ¼ 7.5 Hz), 0.93 (t, 3H,
J ¼ 7.5 Hz); 13C NMR (160 MHz, CD3OD): d 161.22, 161.21, 144.27,
142.15, 143.16, 140.86, 140.82, 136.61, 131.93, 130.52, 130.50,
129.95, 129.88, 129.81, 129.73, 129.69, 128.75, 128.55, 127.62,
127.27, 127.19, 126.94, 119.25, 52.40, 49.89, 28.86, 22.86, 21.74,
12.58.
4.8.2. Bis-sodium salt of 4-butyl-N,N0-bis{[20-(2H-tetrazol-5-yl)]
biphenyl-4-yl]methyl}imidazolium bromide (12b)
The same procedure was employed for the preparation of so-
dium salt 12b. Yield 83%; tR 12.21 min (20%MeCN/ 100%MeCN in
30 min); ESI-MS (m/z): 615.12 [(M  Na) þ H  Br]; 1H NMR
(400 MHz, CD3OD): d 8.56 (s, 1H), 7.60e7.58 (m, 2H), 7.55e7.50 (m,
2H), 7.47e7.45 (m, 4H), 7.42 (s,1H), 7.26 (d, 2H, J¼ 8.2 Hz), 7.19e7.16
(m, 6H), 5.32 (s, 2H), 5.31 (s, 2H), 2.58 (t, 2H, J ¼ 7.4 Hz), 1.57 (quint,
2H, J¼ 7.4 Hz),1.38 (sext, 2H, J¼ 7.4 Hz), 0.93 (t, 3H, J¼ 7.4 Hz) ppm;
13C NMR (160MHz, CD3OD): d 163.52,144.56,143.12,134.25,133.78,
132.73, 132.17, 132.10, 132.03, 131.98, 130.96, 130.02, 129.50, 129.35,
121.43, 54.68, 52.18, 31.13, 25.15, 24.04, 14.83 ppm.4.9. 4-Butyl-N,N0-bis{[2-carboxybiphenyl-4-yl]methyl}imidazolium
bromide (13)
General procedure 3 was employed for the preparation of 13.
Yield 79%; Rf 0.24 (CHCl3/MeOH/gl. AcOH, 8:2:0.2); tR 16.38 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 545.45
[M  Br]; 1H NMR (400 MHz, CD3OD): d 9.09 (s, 1H), 7.87 (d, 2H,
J ¼ 7.6 Hz), 7.57 (t, 2H, J ¼ 7.6 Hz), 7.53 (s, 1H), 7.49e7.34 (m, 12H),
5.46 (s, 2H), 5.44 (s, 2H), 2.65 (t, 2H, J ¼ 7.3 Hz), 1.59 (quint, 2H,
J ¼ 7.3 Hz), 1.40 (sext, 2H, J ¼ 7.3 Hz), 0.93 (t, 3H, J ¼ 7.3 Hz); 13C
NMR (160 MHz, CD3OD): d 173.38, 144.83, 143.73, 139.69, 138.18,
134.16, 134.58, 133.57, 133.35, 132.72, 131.86, 131.50, 131.45, 130.21,
129.58, 121.68, 54.78, 52.25, 31.19, 25.23, 24.05, 14.81.
4.9.1. 4-Butyl-2-hydroxymethyl-N,N0-bis{[20-(2H-tetrazol-5-yl)-
biphenyl-4-yl]methyl}imidazolium bromide (14)
General procedure 3 was employed for the preparation of 14.
Yield: 83%; Rf 0.29 (CHCl3/MeOH/gl. AcOH, 9:1:0.1); tR 11.59 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 623.37
[MBr]; 1HNMR (400MHz, CD3OD): d7.56e7.54 (m, 2H), 7.50e7.47
(m, 2H), 7.44e7.41 (m, 4H), 7.37 (s, 1H), 7.20 (d, 2H, J¼ 8.1 Hz), 7.16e
7.13 (m, 4H), 7.00 (d, 2H, J¼ 8.1 Hz), 5.46 (s, 2H), 5.42 (s, 2H), 2.51 (t,
2H, J¼ 7.5 Hz), 1.49 (quint, 2H, J¼ 7.5 Hz), 1.32 (sext, 2H, J¼ 7.5 Hz),
0.86 (t, 3H, J¼7.5Hz); 1HNMR(400MHz,DMSO-d6): d7.69e7.53 (m,
9H), 7.35 (d, 2H, J ¼ 8.0 Hz), 7.17e7.12 (m, 6H), 6.26 (s, 1H), 5.53 (s,
2H), 5.48 (s, 2H), 4.92 (s, 2H), 2.40 (t, 2H, J¼ 7.4 Hz), 1.36 (quint, 2H,
J¼ 7.4 Hz),1.22 (sext, 2H, J¼ 7.4 Hz), 0.79 (t, 3H, J¼ 7.4 Hz); 13C NMR
(160 MHz, CD3OD): d 161.22, 160.00, 145.06, 142.04, 141.62, 140.90,
135.96, 132.11, 132.02, 129.74, 129.71, 129.66, 125.68, 125.63, 119.28,
119.06, 51.38, 51.17, 48.09, 28.82, 23.05, 21.68, 12.54.
4.9.2. 4-Butyl-2-hydroxymethyl-N,N0-bis{[20-carboxybiphenyl-4-yl]
methyl}imidazolium bromide (15)
General procedure 3 was employed for the preparation of 15.
Yield: 85%;Rf0.22 (CHCl3/MeOH/gl. AcOH8:2:0.2); tR16.01min (10%
MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 575.50 [M Br]; 1H
NMR (400MHz, CD3OD): d 7.86 (t, 2H, J¼ 7.0 Hz), 7.60e7.56 (m, 2H),
7.51 (s, 1H), 7.49e7.35 (m, 10H), 7.24 (d, 2H, J ¼ 8.0 Hz), 5.62 (s, 2H),
5.59 (s, 2H), 5.00 (s, 2H), 2.60 (t, 2H, J ¼ 7.4 Hz), 1.55 (quint, 2H,
J¼ 7.4 Hz),1.37 (sext, 2H, J¼ 7.4 Hz), 0.89 (t, 3H, J¼ 7.4 Hz); 13C NMR
(160 MHz, CD3OD): d 171.46, 145.12, 142.36, 141.95, 140.76, 140.72,
136.11, 132.99, 132.71, 132.67, 130.44, 130.19, 129.08, 127.47, 127.14,
127.05, 125.97, 119.30, 51.37, 51.24, 28.82, 23.13, 21.73, 12.51.
4.10. General procedure 5: halogenation of 4(5)-butylimidazole
4.10.1. 5-Butyl-4-chloro-1H-imidazole (16c)
To a solution of 5a (1.00 g, 8.05 mmol) in anhydrous DMF (5 mL)
was added NCS (1.18 g, 8.86 mmol) in three portions at 0 C. The
reaction mixture was allowed to warm to rt over a period of 2 h
before being quenched with H2O (5 mL) and extracted with CH2Cl2
(3 20mL). The combined organic phases werewashedwith brine,
dried over Na2SO4, ﬁltered and concentrated in vacuo. The oily
residue was puriﬁed by ﬂash column chromatography (silica gel,
CHCl3/MeOH 95:5) to afford the title compound 16c as awhite solid.
Yield: 73%; m.p. 103e105 C; Rf 0.21 (CHCl3/MeOH, 95:5); tR
8.82min (5%MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 159.16
[MþH] (35Cl),161.11 [MþHþ 2] (37Cl); 1HNMR (400MHz, CD3OD):
d 7.44 (s, 1H), 2.68 (t, 2H, J ¼ 7.5 Hz), 1.66 (quint, 2H, J¼ 7.5 Hz), 1.46
(sext, 2H, J ¼ 7.5 Hz), 0.93 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz,
CD3OD): d 133.04, 126.14, 124.24, 31.05, 23.23, 22.0, 12.98.
4.10.2. 4-Bromo-5-butyl-1H-imidazole (16d)
The same procedure was employed for the preparation of 16d.
Yield: 71%; m.p. 109e111 C; Rf 0.21 (CHCl3/MeOH/95:5); tR
G. Agelis et al. / European Journal of Medicinal Chemistry 62 (2013) 352e370 3658.42min (5%MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 203.15
[M þ H] (79Br), 205.11 [M þ H þ 2] (81Br); 1H NMR (400 MHz,
CD3OD): d 2.48 (t, 2H, J ¼ 7.5 Hz), 1.50 (quint, 2H, J ¼ 7.5 Hz), 1.27
(sext, 2H, J ¼ 7.5 Hz), 0.88 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz,
CD3OD): d 137.91, 132.64, 114.53, 34.66, 27.43, 25.56, 16.58.
4.10.3. 5-Butyl-4-iodo-1H-imidazole (16e)
The same procedure was employed for the preparation of 16e.
Yield: 72%; m.p. 93e95 C; Rf 0.21 (CHCl3/MeOH/95:5); tR 8.94 min
(5%MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 250.85 [MþH],
500.80 [2M þ H]; 1H NMR (400 MHz, CD3OD): d 7.73 (s, 1H), 2.59 (t,
2H, J¼ 7.5 Hz), 1.60 (quint, 2H, J¼ 7.5 Hz), 1.35 (sext, 2H, J¼ 7.5 Hz),
0.96 (t, 3H, J¼ 7.5 Hz); 13C NMR (160MHz, CD3OD): d 140.56,137.92,
81.92, 34.98, 28.90, 25.62, 16.72.
4.11. General procedure 6: bis-alkylation of 16cee with the
alkylating agent 6a
4.11.1. 5-Butyl-4-chloro-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]
biphenyl-4-yl]methyl}imidazolium bromide (17c)
To a solution of 16c (0.20 g, 1.26 mmol) in anhydrous THF (5 mL)
under Ar atmosphere were sequentially added anhydrous K2CO3
(0.34 g, 2.50 mmol), a catalytic amount of 18-crown-6-ether as
a phase transfer catalyst and the alkylating agent 6a (1.61 g,
2.89 mol). The reaction mixture was stirred under reﬂux over
a period of 12 h before being quenched with H2O (10 mL) and
extracted with CH2Cl2 (3  20 mL). The combined organic extracts
were dried over Na2SO4, ﬁltered and concentrated in vacuo. Flash
column chromatography (silica gel, CHCl3/MeOH 98:2) afforded 17c
as a yellow foam. Yield: 57%; Rf 0.49 (CHCl3/MeOH/9:1); tR
16.81 min (70% MeCN / 100% MeCN in 30 min); ESI-MS (m/z):
1111.82 [M  Br]; 1H NMR (400 MHz, CDCl3): d 11.46 (s, 1H), 7.95e
7.93 (m, H), 7.33e7.14 (m, 32H), 6.93e6.90 (m, 12H), 5.44 (s, 2H),
5.42 (s, 2H), 2.37 (t, 2H, J ¼ 7.5 Hz), 1.28e1.19 (m, 4H), 0.82 (t, 3H,
J ¼ 7.5 Hz).
4.11.2. 4-Bromo-5-butyl-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]
biphenyl-4-yl]methyl}imidazolium bromide (17d)
The same procedure as above was employed for the preparation
of 17d. Yield: 55%; Rf 0.50 (CHCl3/MeOH 9:1); tR 16.90 min (70%
MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 1157.11 [M Br]; 1H
NMR (400MHz, CDCl3): d 11.28 (s,1H), 7.89e7.64 (m, 2H), 7.42e7.09
(m, 32H), 6.86e6.84 (m, 12H), 5.38 (s, 4H), 2.33 (t, 2H, J ¼ 7.5 Hz),
1.49e1.17 (m, 4H), 0.94 (t, 3H, J ¼ 7.5 Hz).
4.11.3. 5-Butyl-4-iodo-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]
biphenyl-4-yl]methyl}imidazolium bromide (17e)
The same procedure as above was employed for the preparation
of 17e. Yield: 52%; Rf 0.50 (CHCl3/MeOH 9:1); tR 16.31 min (70%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 1203.60 [M  Br];
1H NMR (400 MHz, CDCl3): d 10.88 (s, 1H), 7.94e7.89 (m, 2H), 7.48e
7.15 (m, 32H), 6.92e6.89 (m, 12H), 5.38 (s, 2H), 5.36 (s, 2H), 2.60 (t,
2H, J ¼ 7.5 Hz), 1.56e1.19 (m, 4H), 0.83 (t, 3H, J ¼ 7.5 Hz).
4.12. General procedure 7: bis-alkylation of 16cee with the
alkylating agent 6b
4.12.1. 5-Butyl-4-chloro-N,N0-bis{[20-(tert-butoxycarbonyl)
biphenyl-4-yl]methyl}imidazolium bromide (18c)
To a solution of 16c (0.20 g, 1.26 mmol) in anhydrous Tol (4 mL)
under Ar atmosphere were sequentially added powdered KOH
(0.14 g, 2.52 mmol), a catalytic amount of 18-crown-6-ether as
a phase transfer catalyst and the alkylating agent 6b (1.00 g,
2.90 mol). The reactionmixturewas stirred at 80 C over a period of
12 h before being quenched with H2O (10 mL) and extracted withCH2Cl2 (3 20 mL). The combined organic extracts were dried over
Na2SO4, ﬁltered and concentrated in vacuo. Flash column chro-
matography (silica gel, CHCl3/MeOH 97:3) afforded 18c as a yellow
foam. Yield: 61%; Rf 0.35 (CHCl3/MeOH 9:1); tR 11.52 min (60%
MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 691.53 [M  Br]
(35Cl), 693.54 [Mþ 2 Br] (37Cl); 1H NMR (400MHz, CDCl3): d 11.46
(s, 1H), 7.73 (d, 2H, J¼ 7.6 Hz), 7.50 (d, 2H, J¼ 8.0 Hz), 7.43e7.28 (m,
8H), 7.21e7.16 (m, 4H), 5.60 (s, 2H), 5.57 (s, 2H), 2.52 (t, 2H,
J ¼ 7.5 Hz), 1.35e1.24 (m, 4H), 1.20 (s, 9H), 1.17 (s, 9H), 0.82 (t, 3H,
J ¼ 7.5 Hz).
4.12.2. 4-Bromo-5-butyl-N,N0-bis{[20-(tert-butoxycarbonyl)
biphenyl-4-yl]methyl}imidazolium bromide (18d)
The same procedure as above was employed for the preparation
of 18d. Yield: 64%; Rf 0.36 (CHCl3/MeOH 9:1); tR 11.34 min (60%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 736.45 [M  Br]
(79Br), 738.51 [M þ 2  Br] (81Br); 1H NMR (400 MHz, CDCl3):
d 11.46 (s, 1H), 7.72 (d, 2H, J ¼ 7.5 Hz), 7.48 (d, 2H, J ¼ 8.0 Hz), 7.41e
7.27 (m, 8H), 7.21e7.16 (m, 4H), 5.59 (s, 2H), 5.56 (s, 2H), 2.54 (t, 2H,
J ¼ 7.5 Hz), 1.37e1.25 (m, 4H), 1.22 (s, 9H), 1.18 (s, 9H), 0.84 (t, 3H,
J ¼ 7.5 Hz).
4.12.3. 5-Butyl-4-iodo-N,N0-bis{[20-(tert-butoxycarbonyl)biphenyl-
4-yl]methyl}imidazolium bromide (18e)
The same procedure as above was employed for the preparation
of 18e. Yield: 58%; Rf 0.36 (CHCl3/MeOH 9:1); tR 11.76 min (60%
MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 783.43 [M Br]; 1H
NMR (400 MHz, CDCl3): d 11.53 (s, 1H), 7.72 (d, 2H, J ¼ 7.5 Hz), 7.51
(d, 2H, J¼ 8.0 Hz), 7.43e7.28 (m, 8H), 7.21e7.16 (m, 4H), 5.59 (s, 4H),
2.51 (t, 2H, J ¼ 7.4 Hz), 1.35e1.24 (m, 4H), 1.20 (s, 9H), 1.17 (s, 9H),
0.83 (t, 3H, J ¼ 7.4 Hz).
4.13. 5-Butyl-4-chloro-N,N0-bis{[20-[2H-tetrazol-5-yl]biphenyl-4-
yl]methyl}imidazolium bromide (19c)
General procedure 3 was employed for the preparation of 19c.
Yield: 82%; Rf 0.40 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 13.29 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 628.55
[M  Br] (35Cl), 630.50 [M þ 2  Br] (37Cl); 1H NMR (400 MHz,
CD3OD): d 9.12 (s,1H), 7.69e7.66 (m, 4H), 7.60e7.54 (m, 4H), 7.34 (d,
2H, J ¼ 8.0 Hz), 7.29 (d, 2H, J ¼ 8.0 Hz), 7.23e7.20 (m, 4H), 5.45 (s,
2H), 5.44 (s, 2H), 2.68 (t, 2H, J ¼ 7.4 Hz), 1.39e1.30 (m, 4H), 0.87 (t,
3H, J ¼ 7.4 Hz); 13C NMR (160 MHz, CD3OD): d 156.35, 145.39,
141.54, 141.08, 140.96, 133.99, 132.72, 132.45, 131.52, 131.49, 130.80,
130.60, 130.22, 130.12, 128.55, 128.38, 128.20, 126.69, 123.57, 119.89,
51.55, 51.10, 29.44, 23.21, 22.12, 13.28.
4.13.1. 4-Bromo-5-butyl-N,N0-bis{[20-[2H-tetrazol-5-yl]biphenyl-4-yl]
methyl}imidazolium bromide (19d)
General procedure 3 was employed for the preparation of 19d.
Yield: 80%; Rf 0.43 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 13.17 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 671.37
[M  Br] (79Br), 673.32 [M þ 2  Br] (81Br); 1H NMR (400 MHz,
CD3OD): d 9.12 (s, 1H), 7.66e7.63 (m, 4H), 7.57e7.52 (m, 4H), 7.32 (d,
2H, J ¼ 8.0 Hz), 7.26e7.19 (m, 4H), 7.07 (d, 2H, J ¼ 8.0 Hz), 5.44 (s,
2H), 5.41 (s, 2H), 2.67 (t, 2H, J ¼ 7.4 Hz), 1.40e1.30 (m, 4H), 0.88 (t,
3H, J ¼ 7.4 Hz); 13C NMR (160 MHz, CD3OD): d 156.42, 156.35,
145.33, 141.10, 135.09, 133.58, 132.17, 131.93, 130.62, 130.30, 130.21,
129.85, 128.68, 127.76, 124.18, 106.82, 51.65, 51.04, 29.23, 22.78,
21.77, 13.74.
4.13.2. 5-Butyl-4-iodo-N,N0-bis{[20-[2H-tetrazol-5-yl]biphenyl-4-yl]
methyl}imidazolium bromide (19e)
General procedure 3 was employed for the preparation of 19e.
Yield: 79%; Rf 0.43 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 13.0 min (20%
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NMR (400 MHz, CD3OD): d 9.24 (s, 1H), 7.67e7.62 (m, 4H), 7.59e
7.53 (m, 4H), 7.30 (d, 2H, J ¼ 8.0 Hz), 7.29e7.21 (m, 4H), 7.09 (d,
2H, J¼ 8.0 Hz), 5.50 (s, 2H), 5.43 (s, 2H), 2.70 (t, 2H, J¼ 7.5 Hz),1.37e
1.30 (m, 4H), 0.97 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz, CD3OD):
d 157.52, 146.43, 140.59, 135.75, 133.49, 133.07, 131.23, 130.72,
130.55, 130.15, 129.93, 129.41, 128.01 127.56, 126.08, 89.85, 51.80,
50.04, 29.23, 22.78, 21.77, 13.74.
4.13.3. 5-Butyl-4-chloro-N,N0-bis{[20-carboxybiphenyl-4-yl]methyl}
imidazolium bromide (20c)
General procedure 3 was employed for the preparation of 20c.
Yield: 79%; Rf 0.26 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 17.35 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 579.34
[M  Br] (35Cl), 581.36 [M þ 2  Br] (37Cl); 1H NMR (400 MHz,
CD3OD): d 9.14 (s, 1H), 7.82e7.79 (m, 2H), 7.51 (td, 2H, J ¼ 7.6 Hz,
1.4 Hz), 7.42e7.28 (m, 12H), 5.44 (s, 2H), 5.43 (s, 2H), 2.68 (t, 2H,
J ¼ 7.5 Hz), 1.40e1.22 (m, 4H), 0.83 (t, 3H, J ¼ 7.5 Hz); 13C NMR
(160 MHz, CD3OD): d 173.58, 148.32, 145.51, 143.69, 134.57, 132.87,
132.50, 132.35, 131.59, 130.45, 130.17, 129.82, 129.52, 123.91, 54.78,
52.25, 31.19, 25.23, 24.05, 14.81.
4.13.4. 4-Bromo-5-butyl-N,N0-bis{[20-carboxybiphenyl-4-yl]
methyl}imidazolium bromide (20d)
General procedure 3 was employed for the preparation of 20d.
Yield: 76%; Rf 0.26 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 17.27 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 623.30
[M  Br] (79Br), 625.32 [M þ 2  Br] (81Br); 1H NMR (400 MHz,
CD3OD): d 9.24 (s, 1H), 7.81e7.78 (m, 2H), 7.49 (td, 2H, J ¼ 7.5 Hz,
1.3 Hz), 7.42e7.27 (m, 12H), 5.46 (s, 2H), 5.39 (s, 2H), 2.67 (t, 2H,
J ¼ 7.4 Hz), 1.33e1.29 (m, 4H), 0.84 (t, 3H, J ¼ 7.4 Hz); 13C NMR
(160 MHz, CD3OD): d 173.30, 148.38, 145.00, 144.89, 143.18, 137.39,
135.14, 134.32, 133.75, 132.91, 132.55, 131.59, 131.47, 130.12, 129.81,
129.56, 129.52, 109.14, 54.67, 53.52, 31.56, 25.18, 24.16, 14.77.
4.13.5. 5-Butyl-4-iodo-N,N0-bis{[20-carboxybiphenyl-4-yl]methyl}
imidazolium bromide (20e)
General procedure 3 was employed for the preparation of 20e.
Yield: 73%; Rf 0.26 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 17.42 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 671.31
[M  Br]; 1H NMR (400 MHz, CD3OD): d 9.20 (s, 1H), 7.81e7.79 (m,
2H), 7.50 (td, 2H, J ¼ 1.2, 7.5 Hz), 7.42e7.28 (m, 12H), 5.45 (s, 2H),
5.42 (s, 2H), 2.67 (t, 2H, J ¼ 7.3 Hz), 1.38e1.23 (m, 4H), 0.83 (t, 3H,
J ¼ 7.3 Hz); 13C NMR (160 MHz, CD3OD): d 173.41, 147.88, 144.86,
144.68, 143.40, 141.99, 134.32, 134.11, 133.08, 132.58, 132.55, 131.53,
131.37, 129.98, 129.64, 129.50, 80.86, 56.12, 53.28, 31.93, 26.47,
24.20, 14.75.
4.14. 5-Butyl-4-chloro-2-hydroxymethyl-N,N0-bis{[20-[2-(trityl)
tetrazol-5-yl]biphenyl-4-yl]methyl}imidazolium bromide (21c)
General procedure 2 was employed for the preparation of 2c.
Yield: 76%; Rf 0.45 (CHCl3/MeOH 9:1); tR 16.68 min (70%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 1141.47 [M  Br],
901.43 [(M  Tr) þ H  Br], 242.98 [Tr]; 1H NMR (400 MHz, CDCl3):
d 7.92e7.86 (m, 2H), 7.47e7.45 (m, 5H), 7.32e7.13 (m, 27H), 6.98e
6.71 (m, 12H), 5.76 (s, 2H), 5.67 (s, 2H), 4.73 (s, 2H), 2.51 (t, 2H,
J ¼ 7.5 Hz), 1.29e1.19 (m, 4H), 0.84 (t, 3H, J ¼ 7.5 Hz).
4.14.1. 4-Bromo-5-butyl-2-hydroxymethyl-N,N0-bis{[20-[2-(trityl)
tetrazol-5-yl]biphenyl-4-yl]methyl}imidazolium bromide (21d)
General procedure 2 was employed for the preparation of 21d.
Yield: 72%; Rf 0.44 (CHCl3/MeOH 9:1); tR 15.90 min (70%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 1187.21 [M  Br];
1H NMR (400 MHz, CDCl3) d 7.91e7.88 (m, 2H), 7.42e7.40 (m, 5H),7.25e7.08 (m, 27H), 6.86e6.84 (m, 12H), 5.51 (s, 2H), 4.44 (s, 2H),
2.46 (t, 2H, J ¼ 7.5 Hz), 1.21e1.19 (m, 4H), 0.79 (t, 3H, J ¼ 7.5 Hz).
4.14.2. 5-Butyl-2-hydroxymethyl-4-iodo-N,N0-bis{[20-[2-(trityl)
tetrazol-5-yl]biphenyl-4-yl]methyl}imidazolium bromide (21e)
General procedure 2 was employed for the preparation of 21e.
Yield: 70%; Rf 0.46 (CHCl3/MeOH 9:1); tR 15.31 min (70%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 1234.37 [M  Br]þ;
1H NMR (400 MHz, CDCl3) d 7.92e7.85 (m, 2H), 7.43e7.40 (m, 5H),
7.33e7.06 (m, 27H), 6.89e6.80 (m, 12H), 5.69 (s, 2H), 5.61 (s, 2H),
4.48 (s, 2H), 2.54 (t, 2H, J ¼ 7.5 Hz), 1.25e1.19 (m, 4H), 0.86 (t, 3H,
J ¼ 7.5 Hz).
4.14.3. 5-Butyl-4-chloro-2-hydroxymethyl-N,N0-bis{[20-(tert-
butoxycarbonyl)biphenyl-4-yl]methyl}imidazolium bromide (22c)
The same procedure as above was employed for the preparation
of 22c. Yield: 78%; Rf 0.32 (CHCl3/MeOH 9:1); tR 10.59 min (60%
MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 721.45 [M  Br]
(35Cl), 723.46 [M þ 2  Br] (37Cl); 1H NMR (400 MHz, CDCl3): d 7.78
(d, 2H, J ¼ 7.6 Hz), 7.48 (t, 2H, J ¼ 7.5 Hz), 7.40 (t, 2H, J ¼ 7.5 Hz),
7.35e7.22 (m, 8H), 7.11 (d, 2H, J ¼ 7.6 Hz), 5.86 (s, 2H), 5.79 (s, 2H),
4.83 (s, 2H), 2.68 (t, 2H, J ¼ 7.5 Hz), 1.41e1.26 (m, 4H), 1.25 (s, 9H),
1.23 (s, 9H), 0.90 (t, 3H, J ¼ 7.5 Hz).
4.14.4. 4-Bromo-5-butyl-2-hydroxymethyl-N,N0-bis{[20-(tert-
butoxycarbonyl)biphenyl-4-yl]methyl}imidazolium bromide (22d)
The same procedure as above was employed for the preparation
of 22d. Yield: 75%; Rf 0.33 (CHCl3/MeOH 9:1); tR 10.42 min (60%
MeCN/ 100% MeCN in 30 min); ESI-MS (m/z): 765.56 [M  Br]
(79Br), 767.57 [M þ 2  Br] (81Br); 1H NMR (400 MHz, CDCl3): d 7.79
(d, 2H, J ¼ 7.4 Hz), 7.49 (t, 2H, J ¼ 7.3 Hz), 7.41 (t, 2H, J ¼ 7.3 Hz),
7.35e7.23 (m, 8H), 7.12 (d, 2H, J ¼ 7.6 Hz), 5.92 (s, 2H), 5.84 (s, 2H),
4.82 (s, 2H), 2.70 (t, 2H, J ¼ 7.5 Hz), 1.58e1.36 (m, 4H), 1.27 (s, 9H),
1.25 (s, 9H), 0.93 (t, 3H, J ¼ 7.1 Hz).
4.14.5. 5-Butyl-2-hydroxymethyl-4-iodo-N,N0-bis{[20-(tert-
butoxycarbonyl)biphenyl-4-yl]methyl}imidazolium bromide (22e)
The same procedure as above was employed for the preparation
of 22e. Yield: 74%; Rf 0.35 (CHCl3/MeOH 9:1); tR 10.42 min (60%
MeCN/ 100%MeCN in 30min); ESI-MS (m/z): 813.48 [M Br]; 1H
NMR (400 MHz, CDCl3): d 7.79 (d, 2H, J ¼ 7.6 Hz), 7.49 (t, 2H,
J ¼ 7.4 Hz), 7.41 (t, 2H, J ¼ 7.4 Hz), 7.35e7.19 (m, 8H), 7.10 (d, 2H,
J ¼ 7.6 Hz), 5.90 (s, 2H), 5.83 (s, 2H), 4.79 (s, 2H), 2.73 (t, 2H,
J ¼ 7.5 Hz), 1.52e1.35 (m, 4H), 1.27 (s, 9H), 1.26 (s, 9H), 0.94 (t, 3H,
J ¼ 7.5 Hz).
4.15. 5-Butyl-4-chloro-2-hydroxymethyl-N,N0-bis{[20-[2H-tetrazol-
5-yl]biphenyl-4-yl]methyl}imidazolium bromide (23c)
General procedure 3 was employed for the preparation of 23c.
Yield: 77%; Rf 0.35 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 12.78 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 657.20
[M  Br] (35Cl), 659.23 [M þ 2  Br] (37Cl); 1H NMR (400 MHz,
CD3OD): d 7.68e7.66 (m, 4H), 7.60e7.56 (m, 4H), 7.24e7.07 (m, 8H),
5.64 (s, 2H), 5.62 (s, 2H), 4.95 (s, 2H), 2.66 (t, 2H, J ¼ 7.5 Hz), 1.36e
1.29 (m, 4H), 0.83 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz, CD3OD):
d 155.32,146.23,143.96,141.18,140.06,133.14,132.62,131.98,131.12,
130.39, 130.17, 129.68, 129.53, 129.03, 127.89, 127.82, 126.96, 126.44,
125.86, 122.98, 54.39, 49.09, 29.14, 22.26, 21.68, 12.40.
4.15.1. 4-Bromo-5-butyl-2-hydroxymethyl-N,N0-bis{[20-[2H-
tetrazol-5-yl]biphenyl-4-yl]methyl}imidazolium bromide (23d)
General procedure 3 was employed for the preparation of 23d.
Yield: 77%; Rf 0.34 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 12.78 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 701.40
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CD3OD): d 7.65e7.63 (m, 4H), 7.55e7.51 (m, 4H), 7.18e7.03 (m, 8H),
5.60 (s, 2H), 5.59 (s, 2H), 4.90 (s, 2H), 2.61 (t, 2H, J ¼ 7.5 Hz), 1.33e
1.23 (m, 4H), 0.83 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz, CD3OD):
d 156.74,156.67,146.69,143.99,141.12,141.10,140.53,134.81,133.58,
132.91, 132.45, 130.26, 129.76, 129.56, 127.77, 126.65, 126.27, 124.61,
107.35, 50.29, 49.22, 29.35, 23.06, 21.74, 12.46.
4.15.2. 5-Butyl-2-hydroxymethyl-4-iodo-N,N0-bis{[20-[2H-tetrazol-
5-yl]biphenyl-4-yl]methyl}imidazolium bromide (23e)
General procedure 3 was employed for the preparation of 23e.
Yield: 75%; Rf 0.36 (CHCl3/MeOH/gl. AcOH 9:1:0.1); tR 12.89 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 749.45
[M  Br]; 1H NMR (400 MHz, CD3OD): d 7.65e7.58 (m, 4H), 7.49e
7.42 (m, 4H), 7.14e7.09 (m, 8H), 5.59 (s, 4H), 4.91 (s, 2H), 2.61 (t,
2H, J ¼ 7.5 Hz), 1.24e1.23 (m, 4H), 0.79 (t, 3H, J ¼ 7.5 Hz); 13C NMR
(160 MHz, CD3OD): d 158.32, 146.58, 141.49, 137.75, 134.59, 134.17,
131.53, 130.82, 130.25, 130.01, 129.51, 128.51, 127.77, 125.58, 89.58,
52.50, 51.54, 29.75, 22.48, 21.52, 12.55.
4.15.3. 5-Butyl-4-chloro-2-hydroxymethyl-N,N0-bis{[20-
carboxybiphenyl-4-yl]methyl}imidazolium bromide (24c)
General procedure 3 was employed for the preparation of 24c.
Yield: 81%; Rf 0.23 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 16.99 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 609.39
[M  Br] (35Cl), 611.34 [M þ 2  Br] (37Cl); 1H NMR (400 MHz,
CD3OD): d 7.80 (d, 2H, J ¼ 7.4 Hz), 7.49 (t, 2H, J ¼ 7.4 Hz), 7.40e7.27
(m,12H), 5.64 (s, 4H), 4.97 (s, 2H, H-6), 2.66 (t, 2H, J¼ 7.5 Hz), 1.30e
1.23 (m, 4H), 0.78 (t, 3H, J ¼ 7.5 Hz); 13C NMR (160 MHz, CD3OD):
d 171.25. 147.78, 144.60, 142.62, 140.76, 134.59, 134.33, 134.08,
132.40, 132.32, 131.50, 131.38, 129.43, 128.82, 128.40, 121.96, 51.62,
51.48, 31.53, 24.68, 24.07, 14.70.
4.15.4. 4-Bromo-5-butyl-2-hydroxymethyl-N,N0-bis{[20-
carboxybiphenyl-4-yl]methyl}imidazolium bromide (24d)
General procedure 3 was employed for the preparation of 24d.
Yield: 77%; Rf 0.24 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 16.91 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 653.34
[M  Br] (79Br), 655.31 [M þ 2  Br] (81Br); 1H NMR (400 MHz,
CD3OD): d 7.78 (d, 2H, J ¼ 7.3 Hz), 7.50 (t, 2H, J ¼ 7.5 Hz), 7.41e7.23
(m, 12H), 5.65 (s, 4H), 4.98 (s, 2H), 2.66 (t, 2H, J ¼ 7.3 Hz), 1.30e1.25
(m, 4H), 0.79 (t, 3H, J ¼ 7.3 Hz); 13C NMR (160 MHz, CD3OD):
d 172.13,147.14,142.65,142.50,140.94,136.11,135.26,132.84,132.39,
130.70, 130.64, 130.50, 129.59, 129.45, 127.55, 127.51, 126.81, 126.51,
107.77, 52.62, 50.79, 49.79, 29.78, 23.57, 22.23, 12.83.
4.15.5. 5-Butyl-2-hydroxymethyl-4-iodo-N,N0-bis{[20-
carboxybiphenyl-4-yl]methyl}imidazolium bromide (24e)
General procedure 3 was employed for the preparation of 24e.
Yield: 75%; Rf 0.25 (CHCl3/MeOH/gl. AcOH 8:2:0.2); tR 16.80 min
(10% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 701.35
[M Br]; 1H NMR (400 MHz, CD3OD): d 7.78 (d, 2H, J¼ 7.4 Hz), 7.50
(td, 2H, J ¼ 0.9, 7.4 Hz), 7.41e7.20 (m, 12H), 5.64 (s, 4H), 4.95 (br s,
2H), 2.67 (t, 2H, J ¼ 7.4 Hz), 1.30e1.19 (m, 4H, H-8), 0.80 (t, 3H,
J ¼ 7.4 Hz); 13C NMR (160 MHz, CD3OD): d 171.53, 150.39, 144.49,
144.30, 142.76, 141.80, 134.95, 134.55, 132.38, 131.48, 131.33, 130.12,
129.43, 128.58, 128.37, 120.49, 120.16, 82.07, 54.73, 51.70, 32.12,
26.94, 24.23, 14.78.
4.16. 2-Butyl-N,N0-bis{[20-[2-(trityl)tetrazol-5-yl]biphenyl-4-yl]
methyl}imidazolium bromide (25)
General procedure 1 was employed for the preparation of 25.
Yield: 85%; m.p. 152e154 C; Rf 0.50 (CHCl3/MeOH, 96:4); tR
15.61 min (70% MeCN / 100% MeCN in 30 min); ESI-MS (m/z):1078.89 [M  Br], 835.61 [(M  Tr) þ H  Br], 243.20 [Tr]; 1H NMR
(400 MHz, CDCl3): d 7.96e7.94 (m, 2H), 7.50e7.47 (m, 6H), 7.34e
7.07 (m, 28H), 6.93e6.91 (m, 12H), 5.31 (s, 4H), 2.86 (t, 2H,
J ¼ 7.3 Hz), 1.30e1.22 (m, 4H), 0.79 (t, 3H, J ¼ 7.3 Hz).
4.16.1. 2-Butyl-N,N0-bis{[20-(tert-butoxycarbonyl)]biphenyl-4-yl]
methyl}imidazolium bromide (26)
General procedure 1 was employed for the preparation of 26.
Yield: 84%; m.p.148e151 C; Rf 0.51 (CHCl3/MeOH, 9:1); tR 9.84min
(60% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 657.63
[M  Br]; 1H NMR (400 MHz, CDCl3) d 7.80 (dd, 2H, J ¼ 1.2, 7.6 Hz),
7.52 (s, 2H), 7.48 (dd, 2H, J ¼ 1.2, 7.6 Hz), 7.42e7.36 (m, 10H), 7.27e
7.25 (m, 2H), 5.58 (s, 4H), 3.26 (t, 2H, J¼ 7.2 Hz), 1.42e1.23 (m, 22H),
0.88 (t, 3H, J ¼ 7.2 Hz).
4.17. 2-Butyl-N,N0-bis{[20-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}
imidazolium bromide (27)
General procedure 3 was employed for the preparation of 27.
Yield: 84%; Rf 0.30 (CHCl3/MeOH/gl. AcOH, 9:1:0.1); tR 11.66 min
(20% MeCN / 100% MeCN in 30 min); ESI-MS (m/z): 593.39
[M  Br]; 1H NMR (400 MHz, CD3OD): d 7.67e7.54 (m, 10H), 7.26e
7.19 (m, 8H), 5.43 (s, 4H), 3.03 (t, 2H, J ¼ 7.2 Hz), 1.36e1.28 (m, 4H),
0.84 (t, 3H, J¼ 7.2 Hz); 13C NMR (160MHz, CD3OD): d 161.99,147.76,
143.85, 140.88, 134.24, 132.98, 130.49, 130.27, 130.21, 129.77, 129.40,
127.74, 127.43, 124.22, 122.01, 51.07, 30.70, 21.98, 20.31, 12.35.
4.17.1. 2-Butyl-N,N0-bis{[20-carboxybiphenyl-4-yl]methyl}
imidazolium bromide (28)
General procedure 3 was employed for the preparation of 28.
Yield: 80%; m.p. 129e132 C; Rf 0.22 (CHCl3/MeOH/gl. AcOH,
8:2:0.2); tR 16.13min (10%MeCN/ 100%MeCN in 30min); ESI-MS
(m/z): 545.46 [M  Br]; 1H NMR (400 MHz, CD3OD): d 7.87 (d, 2H,
J ¼ 7.5 Hz), 7.65 (s, 2H), 7.59 (t, 2H, J ¼ 7.5 Hz), 7.47e7.45 (m, 12H),
5.51 (s, 4H), 3.13 (t, 2H, J ¼ 7.4 Hz), 1.39e1.30 (m, 4H), 0.87 (t, 3H,
J ¼ 7.4 Hz); 13C NMR (160 MHz, CD3OD): d 170.29, 147.84, 142.40,
141.35, 132.70, 131.29, 131.05, 131.40, 129.58, 129.18, 127.29, 122.03,
51.25, 28.23, 23.00, 22.07, 12.34.
4.18. 2-Butyl-4-chloro-5-hydroxymethyl-N,N0-bis{[20-(2H-tetrazol-
5-yl)biphenyl-4-yl]methyl}imidazolium bromide (30)
General procedures 6 and 3 were employed for the preparation
of 30. Yield: 77%; m.p. 159e162 C; Rf 0.34 (CHCl3/MeOH/gl. AcOH,
9:1:0.1); tR 10.93min (20%MeCN/ 100%MeCN in 30min); ESI-MS
(m/z): 657.44 [M  Br] (35Cl), 659.46 [M þ 2  Br] (37Cl); 1H NMR
(400 MHz, CD3OD): d 7.68e7.64 (m, 4H), 7.59e7.30 (m, 5H), 7.27e
7.20 (m, 7H), 5.66 (s, 2H), 5.58 (s, 2H), 4.65 (s, 2H), 2.71 (t, 2H,
J ¼ 7.5 Hz), 1.32e1.24 (m, 2H), 0.73 (t, 3H, J ¼ 7.5 Hz).
4.19. 2-Butyl-4-chloro-5-hydroxymethyl-N,N0-bis{[20-
carboxybiphenyl-4-yl]methyl}imidazolium bromide (31)
General procedures 7 and 3 were employed for the preparation
of 31. Yield: 74%; m.p. 128e131 C; Rf 0.20 (CHCl3/MeOH/gl. AcOH,
8:2:0.2); tR 16.11 min (10%MeCN/ 100%MeCN in 30min); ESI-MS
(m/z): 609.26 [M  Br] (35Cl), 611.21 [M þ 2  Br] (37Cl); 1H NMR
(400 MHz, CD3OD): d 7.73 (d, 2H, J ¼ 7.5 Hz), 7.46 (t, 2H, J ¼ 7.5 Hz),
7.38e7.36 (m, 6H), 7.27e7.25 (m, 4H), 7.20 (d, 2H, J ¼ 8.0 Hz), 5.62
(s, 2H), 5.54 (s, 2H), 4.63 (s, 2H), 3.01 (t, 2H, J ¼ 7.2 Hz), 1.21 (quint,
2H, J ¼ 7.2 Hz) 1.10 (sext, 2H, J ¼ 7.2 Hz), 0.70 (t, 3H, J ¼ 7.2 Hz); 13C
NMR (160 MHz, CD3OD): d 174.11, 151.61, 144.60, 142.78, 135.77,
134.76, 134.30, 132.56, 132.39, 131.50, 131.31, 129.47, 128.56, 128.30,
122.46, 53.73, 51.76, 51.07, 30.59, 26.33, 24.30, 14.52.
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The3Dmodel of theAT1 receptorused inourdocking studieswas
kindly provided by Tuccinardi et al. [45]. The construction of this
model is based on X-ray bovine rhodopsin structure, molecular
procedure and available site-directed mutagenesis data [46]. Mo-
lecular Docking studies were performed using Glide extra precision
(XP) implemented Induced Fit Docking (IFD) protocol (v5.0) [47e49]
docking programs under the Linux operating system.
The binding site was deﬁned by 20 A inner cubic grid box,
centered on the point that is the center of mass of residues Lys199
and His256. The IFD protocol under the Schrodinger molecular
modeling package was used in order to eliminate clashes between
receptor and ligand atoms and for the receptor to gain partial
ﬂexibility to the receptor. Before the docking simulations, the
complexes were submitted to the protein preparation module of
Schrodinger. Ligands were constructed using the Schrodinger’s
Maestro module and then geometry optimization was performed
for these ligands using PolakeRibiere conjugate gradient (PRCG)
minimization (0.0001 kJA1 mol1 convergence criteria). Proton-
ation states of residues were created using LigPrep and Protein
Preparation modules under the Schrodinger package at neutral pH.
IFD uses the Glide docking program to account the ligand ﬂexibility
and the reﬁnement module and the Prime (v.1.6) program [48,49]
to account for ﬂexibility of the receptor. Schrodinger’s IFD proto-
col model uses the following steps (the description below is taken
from the IFD user manual): (i) Constrained minimization of the
receptor with an RMSD cutoff of 0.18 A. (ii) Initial Glide docking of
each ligand using soft potentials (0.5 van der Waals radii scaling of
non-polar atoms of ligands and receptor using partial charge cutoff
of 0.15). (iii) Derived docking poses were reﬁned using the Prime
Induced Fit module of Schrodinger. Residues within 5.0 A of ligand
poses were minimized in order to form suitable conformations of
poses at the binding site of the receptor. (iv) Glide re-docking of
each proteineligand complex.
4.21. Molecular dynamics simulations
A lipid bilayer of 72 DPPC molecules was simulated under the
CHARMM 36 force ﬁeld [50,51] with all hydrogen atoms explicit,
whereas the aqueous phase (2162 water molecules) was described
by the TIP3P [52] (transferable intermolecular potential 3P) model.
The initial structure for the bilayer was downloaded as a PDB ﬁle by
the following web page: http://terpconnect.umd.edu/wjbklauda/
research/download.html. As far as the 12b molecule, its topology
ﬁle was created by the SwissParam server which is available online:
http://swissparam.ch/ [53]. The abovementioned topology ﬁles are
compatible with the CHARMM force ﬁeld.
All simulations were performed with the molecular dynamics
package GROMACS 4.5.4 [54e57] in the context of NPzAT ensemble
with a constant area per lipid, A, equal to 0.64 nm2/lipid. The
equations of motion were integrated with a time step equal to 2 fs
while temperature was kept constant at 317 K using the Berendsen
thermostat [58] with a coupling time constant equal to 0.1 ps.
Regarding to the pressure along the normal to two DPPC leaﬂets (Z-
axis), it was regulated by the Berendsen barostat [58] at 1 bar, with
a coupling time constant to be 1 ps. LennardeJones and Coulomb
interactions were calculated using a 1.0 nm cut-off radius while the
long range electrostatics were treatedwith the Particle Mesh Ewald
(PME) method [59]. The system was energy-minimized employing
the steepest descent method [57] and after that the MD simulation
was commenced with the 12b molecule initially placed in the
aqueous phase. The whole duration of the simulation is equal to
120 ns whereas the last 40 ns were employed for the calculation of
the properties.4.22. Umbrella sampling simulations
The PMF of the 12b from aqueous to lipid phase was computed
by the Weighted Histogram Analysis Method (WHAM) [60,61] that
is available in GROMACS 4.5.4. In particular, thirty one biasing MD
simulations were conducted along a reaction coordinate z (Z-axis),
which is deﬁned as the distance of the 12b center of mass from the
bilayer center (z¼ 0). In addition, a harmonic potential was applied
(k ¼ 500 kJ/mol/nm2) between bilayer and 12b centers of mass. It
has also to be reported that the simulation system contains 3021
water molecules so as to avoid the interaction of the drug with the
periodic image of the opposite leaﬂet of the bilayer. The duration of
the biasing MD simulations was 24 ns of which the ﬁrst 10 ns was
regarded as an equilibration and therefore they were not taken into
account for the computation of PMF. The rest of the MD parameters
were the same with those given in the previous subsection.
4.23. Quantum chemical calculations
Geometry optimization and HOMO and LUMO calculations were
performed for the studied compounds. The geometries were fully
optimized using Density Functional Theory (DFT) hybrid method
with the Becke’s three-parameter exchange functional and
gradient-corrected functional of Lee, Yang and Parr (B3LYP) [62]
using the following standard basis set: 3e21 g. All geometry opti-
mization were followed by calculations of frequencies in order to
identify obtained structures as energy minima (no imaginary fre-
quencies). All minima for all the compounds were veriﬁed by
establishing that the matrix of energy second derivatives (Hessian)
has only positive eigenvalues (all vibrational frequencies are real).
All calculations were carried out with the Gaussian 09W program.
HOMO and LUMO frontier orbitals of the molecule were also
computed at the same level of theory. Molecular orbital (MO) sur-
faces visually represent the various stable electron distributions of
a molecule. According to Frontier orbital theory [63] the shapes and
symmetries of the highest-occupied and lowest-unoccupied mo-
lecular orbitals (HOMO and LUMO) are crucial in predicting the
reactivity of a species and the stereochemical and regiochemical
outcome of a chemical reaction. Molecules with high HOMO
(highest occupied molecular orbital energy) values are able to
donate electron density more easily than molecules with low
HOMO energy values. The HOMO energy value can be increased
with the presence of electron-donating groups (EDG) such as e
NMe2, eNH2, eNHEt, and eOMe and decreased with the pres-
ence of electron-withdrawing groups (EWG) such as halogens,eCN
and eNO2 groups [64].
4.24. Pharmacological evaluation
4.24.1. AT1 receptor binding assay of synthesized ANGII analogs
4.24.1.1. Cell culture and transfection. Human embryonic kidney
(HEK 293) cells were grown in DMEM/F12 (1:1) containing 3.15 g/L
glucose and 10% bovine calf serum at 37 C and 5% CO2. 60 mm
dishes of HEK 293 cells at 80e90% conﬂuence were transfected
with 3 mg of plasmid DNA encoding the human AT1 receptor, using
9 mL of Lipofectamine and 2 mL of OPTIMEM. To generate stably
transfected pools of cells expressing the AT1 receptor 5e12 h after
transfection, the medium was replaced by DMEM/F12 (1:1) con-
taining 3.15 g/L glucose,10% bovine calf serum and 700 mg/mL of the
antibiotic, Geneticin. The antibiotic used ensured the selection of
a stably transfected pool of cells.
4.24.1.2. Harvesting cells and membrane preparation. HEK 293 cells
(grown in 100 mm dishes) stably expressing the human AT1 re-
ceptor were washed with phosphate-buffered saline (PBS; 4.3 mM
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7.3 at room temperature), brieﬂy treated with PBS containing 2mM
EDTA (PBS/EDTA), and then dissociated in PBS/EDTA. Cell
suspension was centrifuged at 1000 g for 5 min at room
temperature, and the pellet was homogenized in 1 mL of buffer O
(50 mM TriseHCl containing 0.5 mM EDTA, 10% sucrose, 10 mM
MgCl2, pH 7.4 at 4 C) using a Janke & Kunkel IKA Ultra Turrax
T25 homogenizer (at setting w20, 10e15 s, 4 C). The
homogenate was centrifuged at 250 g for 5 min at room
temperature. The pellet was discarded and the supernatant was
centrifuged (16,000 g, 10 min, 4 C). The membrane pellet was
resuspended (0.6e0.7 mL/100 mm dish) in buffer B (50 mM Trise
HCl containing 1 mM EDTA, 10 mM MgCl2, 0.2% BSA, 0.2 mg/mL
bacitracin, and 0.93 mg/mL aprotinin, pH 7.4 at 4 C) and used for
radioligand binding studies.
4.24.1.3. [125I-Sar1-Ile8] ANGII binding. The [125I-Sar1-Ile8] ANGII
competition binding was performed as follows. Aliquots of diluted
membrane suspension (50 mL) were added into tubes, containing
buffer B and 100,000e120,000 cpm [125I-Sar1-Ile8] ANGII with or
without increasing concentrations of ANGII analogs in a ﬁnal vol-
ume of 0.15 mL. The mixtures were incubated (1 h, 24 C) and then,
ﬁltered using a Brandel cell harvester throughWhatman GF/C glass
ﬁber ﬁlters, presoaked for 1 h in 0.5% polyethyleneimine at 4 C. The
ﬁlters were washed 10 times with 1e2 mL of ice-cold 50 mM Trise
HCl containing NaCl 120 mM, pH 7.4 at 4 C. Filters were assessed
for radioactivity in a gamma counter (LKBWallac 1275minigamma,
80% efﬁciency). The amount of membrane used was adjusted to
ensure that speciﬁc binding was always equal to or less than 10% of
the total concentration of the radioligand added. Speciﬁc [125I-Sar1-
Ile8] ANGII binding was deﬁned as the total binding minus non-
speciﬁc binding in the presence of 1000 nM [Sar1-Ile8] ANGII. Data
analysis for competition binding was performed by nonlinear
regression analysis, using GraphPad Prism 4.0 (GraphPad Software,
San Diego, CA). elogIC50 values were obtained by ﬁtting the data
from competition studies to a one-site competition model and
presented as mean plus/minus standard error (SE).
4.24.2. Rat uterotonic test in vitro
The compounds prepared were tested in rat uterotonic in vitro
test [65]. All samples were dissolved in DMSO to make stock so-
lution of 1e4 mg/mL. Further solutions were made in physiological
solution. Standard ANGII was dissolved in physiological solution.
The test was performed in the same way as described for oxytocin
and vasopressin analogs or bradykinin compounds [65e68]. The
pA2 was calculated from at least 3 independent experiments using
uteri from different rats. In brief, the excised and longitudinally cut
strips of rat uterus were placed into a bathing chamber into media
without magnesium ions and mounted to the contraction recorder.
The height of a single isometric contraction of a uterine strip was
measured. The cumulative doseeresponse curves of standard
ANGII were constructed, i.e. doses of standard (in the presence or
absence of an analog) were added successively to the uterus in the
organ bath in doubling concentrations and at 1 min intervals
without the ﬂuid being changed until the maximal response (the
highest contraction) was obtained. The shift of the curves in the
presence of an analog was determined. The concentration of the
analog leading to the shift corresponding to 0.3 in logarithmic scale
(it means that twice higher concentration of the standard was
necessary to apply to reach the half maximal effect) was deter-
mined. Negative logarithm on the base of 10 of that concentration is
pA2. Wistar rats were used in all experiments. Handling of the
experimental animals was done under supervision of the Ethics
Committee of the Academy of Sciences according to x 23 of the law
of the Czech Republic no. 246/1992.Author contribution
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